BioTOP Report 2014

BioTOP-Report 

2014 

Biotech and Pharma in Berlin-Brandenburg

BioTOPics 47 | May 2014 

BioTOP-Report 2014 

Content 

Editorial 

The German Capital Region – Biotechnology and Life Sciences are Ready for the Future 3 

Biotechnology 

The Capital Region – New Jobs and New Companies 4 

Pharma 

Attractive Location 14 

Glycoscience 

Glyco Research for Innovations in Health Industry 18 

Bioelectronics 

The Joint Lab Bioelectronics – A New Platform for the Integration of Microelectronics into Life Sciences 20 

Business Location 

Excellent Services for Berlin-Brandenburg 24 

Spotlight on European Business and Internationalization 

The Enterprise Europe Network Berlin-Brandenburg 26 

Biotech Parks 

The BioCampus Network Berlin-Brandenburg 34 

Addresses 39 

Publisher: Berlin Partner für Wirtschaft und Technologie GmbH · BioTOP Berlin-Brandenburg 

Fasanenstraße 85 · 10623 Berlin · Germany · Phone +49 30 318622–0 · Fax +49 30 318622–22 · biotop@biotop.de · www.healthcapital.de 

Editor: Volker Erb 

Design & Production: webersupiran.berlin 

Translation: Kate Abbott · Berlin 

Photos/Figures: BioTOP or authors and: 

Page 14 Paulus Rusyanto/dreamstime.com, Sean Pavone/dreamstime.com Page 21 Warenemy/dreamstime.com, Collpicto/dreamstime.com 

Page 27 adimas/Fotolia (Profile Alacris), Noah Clayton/co.don (Profile co.don) Page 30 Werner Popp (Profile organobalance).



Editorial 

The German Capital Region – Biotechnology and 

Life Sciences are Ready for the Future 

Berlin-Brandenburg is an extremely attractive location for research and its translation into industrial applications. 

The establishment of the Berlin Institute of Health, successful spin-offs and inward investment show that the German 

capital region provides top conditions for the healthcare industry. Berlin is the start-up capital of Germany! 

With its new “Healthcare Industries” master plan, the capital region 

is setting the course for the sector’s development until 2018. 

Basic research, innovation, spin-offs and application – in the future, 

these will remain the four pillars that determine the successful 

implementation of the cluster strategy in Berlin-Brandenburg. 

Biotechnology/pharmaceuticals, medical technology and the 

healthcare industries are the focal areas. In the coming years, 

biotechnology/pharmaceuticals development will feature: 

The creation of new translation platforms in basic research, 

clinical research and industrial biotechnology 

Max Planck and Fraunhofer Research, as well as the Helmholtz 

and Leibnitz Institutes, are drivers of technology transfer and pioneers 

of innovative technologies and products. 

Development of new growth fields in the life sciences with interdisciplinary 

technologies 

Cross innovation at the interface of microsystems technology, microelectronics, 

photonics and surface engineering and thin films 

open up completely new opportunities for analytics, automation 

and hardware development and along with this, for growth, value 

creation and cost reduction. 

Value chain expansion via inward investment and industrial 

location expansion 

With more than 200 biotechnology companies, over 30 research 

institutions and over 130 clinics and hospitals, Berlin-Brandenburg 

is already a European hot spot for the life sciences. Growth 

in expertise, players and investment will reinforce the capital region’s 

leading position in the international markets. 

Concentration on therapy development through new system 

medicine strategies 

The Max Delbrück Center for Molecular Medicine and Charité – 

Universitätsmedizin Berlin are the umbrella for the new flagship of 

German biomedicine. 

In diagnostics, focus on the development of companion diagnostics 

Laboratory medicine, applied research, SMEs and the pharmaceuticals 

industry are pooling their activities for therapy optimization 

in personalized medicine. 

This new edition of the BioTOP Report provides you with an exciting, 

informative overview of the development in the capital region’s 

industries. With themes such as glyco-engineering technology 

and bioelectronics, it underscores internationally outstanding 

activities. We wish you reading pleasure and invite you to commit 

to Berlin-Brandenburg as a place to develop your business. 

Reach out and contact us! 

In regenerative medicine, concentration on the development of 

new cell therapies 

The Berlin-Brandenburg Center for Regenerative Therapies 

(BCRT), biotechnology SMEs and pharmaceuticals partners in 

the international Regenerative Medicine Coalition are part of a 

high-performance product development network. 

Focus on the sustainable use of biological resources for medical 

applications in industrial biotechnology 

The Leibniz Institute for Agricultural Engineering, university-related 

research and biotechnology SMEs are successfully implementing 

the federal government’s bioeconomics strategy and contributing 

to the strength of the healthcare industries. 

Prof. Dr. Peter Seeberger 

Expert Circle Spokesman 

“Biotech/Pharma“ 

Dr. Günter Peine 

Head of 

BioTOP Berlin-Brandenburg 

3


BioTOP-Report Biotechnology 

Biotechnology 

The Capital Region – New Jobs and New Companies 

The growth trend of recent years continues in 2013. Employee numbers have grown by 5.6 % (last year, 6.5 %). 

Currently, 232 companies employ 4,586 people. The constant momentum is accompanied by many newly founded 

businesses. 

kk 

According to the latest BioTOP survey, 232 biotechnology 

companies are active in the Berlin-Brandenburg region. This 

means the company base has expanded by a total of 10 

companies against last year. 

kk 

A total of 14 companies have stopped doing business in the 

region, either shutting down completely or relocating. 

kk 

The addition of 24 companies more than compensated for 

this loss. Of the new companies, we count 6 additions due 

to inward investment and new registration and – particularly 

notable – 18 start-ups. 

kk 

The current base of 232 companies has created 352 new jobs. 

This translates into a growth rate of over 8 percent. 

kk 

After subtracting the 114 jobs lost due to business shut-downs, 

the sector in the region gained a total of 273 jobs, adding up 

to regional employment growth of 5.6 % in the sector. 

For many years, biotechnology region Berlin-Brandenburg has 

been on a steady growth course. One of the sector’s leading regions 

in Germany and Europe, it hosted 18 start-ups last year 

alone – a figure to note. This speaks volumes in favor of the location’s 

general conditions and the commitment of the many players 

involved and their start-up-related activities. And above all, underscores 

the courage of the many company founders who are 

seeking their fortune in this highly sophisticated sector. 

Smaller companies dominate the region’s business landscape: 

139 companies in the sector have less than 10 employees. Only 

13% of the total jobs are located in these companies, however. 

Over 53% of the sector’s employees in the region work for the 19 

companies with more than 50 employees. 

The majority of these companies (88%) focus on the areas of new 

therapeutic agents, diagnostic products and biopharmaceuticals 

services; followed by 19% in the agriculture/food sectors and 13% 

in the industrial biotechnology sector (multiple mentions). 

The start-ups still have little effect on the job market. At their 

launch, none of these companies had more than 10 employees. 

JANUARY 2013 

Epigenomics AG hands in fourth module at FDA completes application for 

approval as planned +++ co.don ® AG applied for approval of joint cartilage 

product chondrosphere ® in the EU +++ Shire discovered the Munich-based RNA 

specialist Ethris for itself. In cooperation the two companies want to find therapies 

for rare diseases 

FEBRUARY 2013 

Epigenomics receives notice about grant of priority review status and acceptance 

of the hand-in of the PMA application for Epi proColon ® from the FDA +++ 

Innovation forum “Biopolymers and Bio-based Plastics” in Schwarz heide 

MARCH 2013 

BIOTECON Diagnostics GmbH extends its robot segment +++ Epigenomics AG 

collects 5,0 million Euros through capital increase +++ New research collective 

INNO-TRACE develops innovative contrast agents for tumour imaging 

APRIL 2013 

Europe's largest clinical laboratory at Campus Virchow-Klinikum: Labor Berlin 

inaugurates new site 

MAY 2013 

Bayer HealthCare presents new incubator model for biotech start-ups in Berlin 

JUNE 2013 

Alacris Theranostics GmbH announces Illumina CSPro certificate for next generation 

sequencing +++ Humedics co-founder Martin Stockmann receives Von- 

Langenbeck Prize for development of LiMAx test 

JULY 13 

Berlin-Brandenburg Healthcare Industries cluster HealthCapital launches new 

website: www.healthcapital.de +++ Caprotec expands alliance with Bayer +++ 

EZAG AG in participation via subsidiary OctreoPharm Sciences GmbH +++ caprotec 

bioanalytics GmbH and Bayer CropScience enter into second research 

collaboration +++ NOXXON Pharma completes patient recruitment for phase IIa 

study in diabetic nephropathy +++ Romer Labs ® and the Institute for Product 

Quality (ifp) launch new AgraQuant ® F.A.S.T. 

AUGUST 13 

Bayer HealthCare concludes partnership and license agreement with Compugen 

Ltd. for the research, development and marketing of antibody-based drugs 

for cancer immunotherapy. +++ caprotec bioanalytics GmbH and Syngenta International 

AG announce research collaboration +++ Epigenomics AG agreement 

with YA Global Master SPV Ltd. brings funding of up to €5 million 

SEPTEMBER 13 

Eckert & Ziegler BEBIG s.a. takes over prostate cancer implantation business of 

American company Biocompatibles Inc. for $5 million +++ Myelo Therapeutics 

GmbH successfully completes funding round for the development of adjuvant 

cancer therapy 

OCTOBER 13 

Epigenomics and Polymedco sign commercialization agreement for Epi proColon 

® for the North American market +++ Sugar is life: GlycoUniverse successfully 

launched in Campus Buch +++ Cell Medica, a leading company in the T-cell 

4

BioTOPics 47 | 6. Juni 2014 (3:02) 


Dr. Matthias Schroff 

CEO MOLOGEN AG 

Key milestones achieved 

MOLOGEN completed a successful fiscal year 2013 with three 

different product candidates in clinical development for the first 

time. The final evaluations for the completed clinical trials of 

MGN1703 and MGN1601 provided very positive data, and with 

MGN1404 (a product that combats malignant melanoma), the 

company launched the clinical development phase of another 

product candidate within the framework of a partnership, contributing 

to an expansion of its pipeline. For its most advanced product 

candidate, the cancer immunotherapy MGN1703, MOLOGEN 

was also able to present very positive clinical data from the final 

evaluation of a phase II trial in colorectal cancer (IMPACT study) 

in 2013. For the most part, the preparations for a phase III pivotal 

study in this indication were completed in the course of the last 

fiscal year. 

Glycotope specializes in the glycosylation of proteins. Glycotope 

has a broad portfolio of drugs in clinical development, including 

the new cancer drugs, PankoMab-GEX and CetuGEX, both 

in phase IIb trials. PankoMab-GEX is the first fully glycosylated 

and glyco-optimized human antibody for a novel tumor-specific 

carbohydrate-protein mixed epitope (TA-MUC1) abundantly present 

in a larger set of tumor indications, metastases and cancer 

We are well aware that our company’s success is also due to 

the conditions that Berlin and the capital region offer. Whether 

research collaboration (FU Berlin) or clinical studies with 

Charité Universitätsmedizin and its departments – we benefit 

from the close scientific network. The availability of qualified 

personell is also a key advantage, which surely ties into the 

high quality of life in Berlin. Berlin is a city for conferences 

and conventions and many of our sector associations have 

their headquarters here. This is another reason why Berlin is 

an excellent location for medical biotechnology. As a research 

company, we appreciate the fact that Berlin is one of the 

world's leading regions and innovative locations in the field 

of life sciences. 

stem cells. Additional Glycotope products include TrasGEX, 

which has successfully completed its phase I/IIa trial and the improved 

fertility hormone FSH-GEX, which is expected to begin 

two phase III clinical trials in 2014. 

Biopharmaceuticals company NOXXON Pharma is a pioneer in 

the development of a new class of proprietary therapeutic agents 

called “Spiegelmers,” which are chemically synthesized L-ste- 

therapy field, opens a central European production facility in Berlin-Buch +++ 

ProBioGen upholds strong patent position in viral vaccine manufacturing field 

NOVEMBER 13 

Glycotopes Fully Human and Glycooptimized Recombinant FSH-GEX exhibits 

superior activity and excellent tolerability in phase II clinical trial for in vitro 

fertilization +++ The methylated SHOX2 biomarker from Epigenomics shows 

promising results for therapy-related monitoring of lung cancer patients +++ 

SCIENION´s sciFLEXARRAYER receives product technology innovation award 

from Materials Science Society AVS +++ The NeuroPro Alliance, a joint venture 

between the Technical University of Applied Sciences Wildau, nanoPET 

Pharma GmbH and AudioCure Pharma GmbH, receives research award. 

DECEMBER 13 

OMEICOS Therapeutics: new drug for atrial fibrillation in model systems tests 

positively +++ Contichrom ® systems from KNAUER receive Berlin-Brandenburg 

Innovation Award +++ ProBioGen announces expansion of commercial 

licenses with emergent biosolutions for AGE1.CR ® viral vaccine manufacturing 

production platform 

JANUARY 14 

Improved diagnostics for sepsis-associated liver dysfunction with LiMAx test 

from Humedics GmbH +++ Epigenomics starts trading on US OTCQX market 

+++ Cell Medica announces European Union orphan drug designation for 

Cytovir ADV +++ ward-winning Ostendum Lab-on-a-Chip nanodevices are produced 

with SCIENION's sciFLEXARRAYER SX 

FEBRUARY 14 

The Swedish-German company Amal Therapeutics SA has acquired investors 

for a seed financing round +++ mivenion GmbH receives FDA approval for 

Xiralite ® Fluorescence Imaging System X4 for microcirculation visualization +++ 

€15 million for Mologen 

MARCH 14 

Glycotope GmbH raises €55 million +++ FDA Advisory Committee Provides 

Recommendations for Epigenomics' Colorectal Cancer Screening Blood Test 

APRIL 14 

Alacris Theranostics GmbH announces partnership with Walldorfer SAP AG 

+++ On May 14, Bayer HealthCare opened its first German CoLaborator in 

Berlin-Mitte on the company's premises +++ Bayer Pharma AG participates 

in the High-Tech Startup Fund II +++ International pharmaceutical company 

Takeda extends production facility in Oranienburg 

5



reoisomer RNA aptamers and a non-immunogenic alternative 

to antibodies. NOXXON is approaching the completion of multiple 

proof-of-concept studies with a diversified portfolio of clinical-stage 

Spiegelmer ® therapeutic agents exhibiting high safety 

and tolerability, and promising signs of efficacy. Emapticap pegol 

(NOX-E36), an anti-CCL2/MCP-1 Spiegelmer ® , is currently in a 

phase IIa study in patients with diabetic nephropathy. Olaptesed 

pegol (NOX-A12), an anti-CXCL12/SDF-1 Spiegelmer ® , is currently 

in phase IIa studies in two hematological cancers: multiple 

myeloma and chronic lymphocytic leukemia. Lexaptepid pegol 

(NOX-H94), an anti-hepcidin Spiegelmer ® , has shown efficacy in 

a subset of anemic cancer patients with functional iron deficiency 

in a pilot study where the pharmacodynamic parameters of iron 

metabolism and erythropoiesis were positively influenced and 

hemoglobin levels increased following lexaptepid mono-therapy. 

The product will also be evaluated in a phase IIa study in dialysis 

patients with ESA-hyporesponsive anemia. 

2.500 

2.400 

2.300 

2.200 

2.100 

2.000 

1.900 

1.800 

1.700 

1.600 

1.500 

1.400 

1.300 

1.200 

1.100 

1.000 

900 

800 

700 

600 

500 

400 

300 

200 

100 

Number of employees 

Number of Employees According to Company Size 

602 

1.542 

2.442 

0 

'04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 

139 companies 1-10 employees 

74 companies 11-50 employees 19 companies > 51 employees 

In comparison to the previous year, the average number of employees per company decreased by 9,2 % in the 1-10 category 

and increased 15,9 % in the 11-50 category. The average number of employees in the category > 50 employees increased by 3,7 %. 

(Source: Own survey, BioTOP database, 232 companies questioned, February 2014) 

6



Epigenomics, a molecular diagnostics company in the process 

of developing and commercializing a pipeline of proprietary 

products for the screening and diagnosis of cancer, announced 

the outcome of a meeting of the Molecular and Clinical Genetics 

Panel of the FDA’s Medical Devices Advisory Committee held in 

conjunction with its premarket approval for its blood-based colorectal 

cancer screening test Epi proColon ® . The members of the 

Medical Devices Advisory Committee voted favorably, determining 

that the benefits of Epi proColon ® do outweigh the risks for use 

in patients who meet the criteria. 

Caprotec bioanalytics and Syngenta International AG announced 

a joint research agreement in which Syngenta will gain access 

to caprotec’s proprietary capture compound mass spectrometry 

technology. The companies will work together to profile the 

interactions of one of Syngenta’s novel active compounds with 

the proteome in its relevant plant biological system. caprotec’s 

platform enables the unbiased evaluation of the interactions of 

small molecules with protein mixtures in a targeted and directed 

manner, which facilitates the identification and elucidation of tractable 

targets and accelerates the development of promising leads. 

Cell Medica announced that the European Medicines Agency 

(EMA) Committee for Orphan Medicinal Products has issued a 

positive opinion on an application for orphan designation of a 

novel T cell immunotherapy under development by the company. 

The cell therapy Cytovir ADV targets the treatment of adenovirus 

infections in patients following allogeneic hematopoietic stem cell 

(bone marrow) transplant. It is comprised of adenovirus-specific T 

cells derived from allogeneic donor leukocytes, expanded ex vivo. 

5.000 

4.500 

4.000 

3.500 

3.000 

2.500 

2.000 

1.500 

1.000 

500 

0 

Number of employees 

Employees in Biotech SMEs 

'04 '05 '06 '07 '08 '09 '10 '11 '12 

4.586 

Employment rose to 4.586 in 2013. This is a growth of 5,6 % in 

comparison to the previous year. The number of companies went 

up to 232, reflecting the arrival of 24 companies (18 start-ups) 

and 14 departures. (Source: Internal survey, BioTOP database, 

232 companies questioned, February 2014) 

'13 

co.don is one of the world’s leading specialists in the cultivation 

of cells for the joint-preserving treatment of articular cartilage and 

intervertebral disk defects. Using the company’s patented therapeutic 

products, doctors are able to avoid joint and intervertebral 

disk prostheses in many cases. An increasing number of orthopedists, 

orthopedic surgeons and neurosurgeons are relying on this 

regenerative therapeutic procedure. This minimally invasive method 

for articular cartilage regeneration has been successful with 

approx. 6,000 patients in Germany. Experts estimate the overall 

European market to have a potential annual worth of approx. €1.2 

billion. With its current infusion of capital, co.don is paving the 

way for the EU-wide approval of its biological therapeutic co.don 

chondrotransplant ® DISC – an autologous method for treating intervertebral 

disk damage. 

MetrioPharm was able to complete the regulatory pre-clinical 

study package. The most important outcome was MP1032’s 

superior safety profile as confirmed by the results from the various 

regulatory pharmacology and toxicology studies conducted 

throughout the past year. The results of these tests surpassed 

all ambitious expectations. Repeated daily administration of up 

to 150(!) times the normal therapeutic dose for 28 consecutive 

days did not cause any side-effects or adverse events whatsoever. 

A clean safety profile is a highly valuable asset for a new drug. 

With the impeccable animal safety data obtained for MP1032 an 

important foundation for entering clinical Phase I trials in 2014 

was laid. For the first time, MP1032 can now be tested directly in 

humans. 

7



ProBioGen is an internationally operating technology provider 

and contract development and manufacturing organization 

(CDMO) with almost 20 years of experience in cell culture, process 

development and GMP manufacturing. A competent and 

reliable CDMO partner, ProBioGen offers customized solutions 

for even the most challenging development and manufacturing 

requirements. ProBioGen has signed its latest GlymaxX ® ADCC 

technology deal with a top-10 pharmaceuticals company for a 

therapeutic antibody platform. 

Investment in the Region 

In recent months, these companies have acquired financing of 

almost €100 million. Glycotope GmbH has led the field with a 

new financing round of €55 million. Investors have supplied the 

company with €130 million in the past few years. One of the largest 

in Europe, the latest round of financing has attracted international 

attention. It will be exciting to see how Glycotope’s future 

develops. The listed companies have also obtained a new 

infusion of money. Mologen and Epigenomics have been able to 

financially safeguard their next steps with new capital increases, 

for example. High-Tech Gründerfonds (HTGF) and IBB Beteiligungsgesellschaft, 

one of the most active venture capital financiers 

in Germany, were among the most responsive financiers in the 

Dr. Karen Uhlmann 

COO/Co-CEO Omeicos Therapeutics GmbH 

Dr. Robert Fischer 

CSO/Co-CEO Omeicos Therapeutics GmbH 

early-stage area again in 2013. Subsidies from the states of Berlin 

and Brandenburg, which contributed project-related funding 

volumes of 42 Mio. Euro to life sciences companies alone, supplemented 

private funding. Investment helps not only the companies 

involved, but is also relevant for the development of the overall 

biotechnology region, generating useful growth effects above and 

beyond its benefits to individual companies. 

Conclusion 

The Berlin-Brandenburg biotechnology region has enjoyed a constant 

growth trend for years. The companies in the sector have 

again proven their competitiveness in 2013/2014. After many years 

of developing products and conducting the studies required by 

the certifying authorities, the near future will show whether the 

investments have paid off. Most of the biopharmaceutical companies 

are doing so well that is safe to be optimistic, although the 

risk remains high. The region’s pool of highly specialized service 

providers is only one of the factors upon which this excellent economic 

development is based. The companies in the sector grow 

organically and are typically less dependent on external investors. 

They important sector delivers constant, sustainable growth for 

the Berlin-Brandenburg region. 

Relatively strong fluctuation is typical of the still-young biotechnology 

sector. Established companies go and new ones come to 

take their place. The high number of start-ups, which ultimately 

compensate for failed business ventures, is another reason for 

optimism. To ensure the successful development of these young 

companies, private investors must actively participate in early-stage 

financing again. 

OMEICOS Therapeutics is working on a new drug for the treatment of atrial fibrillation, and would like to implement the clinical development 

by the end of 2016. The demand for a new atrial fibrillation treatment is high – and with it, its commercial potential. All of the 

medicines available now to the majority of patients have a limited effect, and some of them go hand in hand with highly problematic 

side effects. Working with their partners at the Texas Southwestern Medical Center, scientists at the Max Delbrück Center for Molecular 

Medicine (MDC) Berlin-Buch have identified a metabolism product of the Omega 3 fatty acid with an anti-arrhythmic effect. Based on 

this product, they have synthesized drug candidate OMT-33. The fact that the active ingredient can be further developed for commercial 

use as part of a start-up is due to the very good general conditions existing before the company was even established. OMEICOS 

received its initial financial support from the MDC PreGO-Bio funds and Helmholtz Enterprise, the spin-off support project of the 

Helmholtz Association. The company received seed financing through a High-Tech Gründerfonds participation and ProFIt funding 

from the state of Berlin, which is co-funded with capital from the European Fund for Regional Development (EFRE). With its BioTech 

Park, Campus Berlin-Buch provides the ideal framework conditions and an outstanding infrastructure for our product development 

phase. Of course the direct proximity to MDC is essential to our success. OMEICOS and MDC will continue to work in close partnership. 

And our cooperation with the Campus' BBB Management GmbH also makes the location very attractive for us. 

8

vfa bio represents the biotech interests within the German Association of 

Research-Based Pharmaceutical Companies (vfa). vfa campaigns for the 

interests of 45 worldwide leading pharmaceutical companies in the fields 

of health, research and economy. 

vfa bio seeks to exploit the therapeutic and economic potential of biotechnology 

to make Germany the leading biotech location in Europe. 

Medical biotechnology is vfa bio’s topic. We primarily deal with: 

▪▪ 

Medical progress provided by biopharmaceuticals - 

benefit for patients, physicians and society as a whole 

▪▪ 

▪▪ 

▪▪ 

▪▪ 

▪▪ 

Access to biopharmaceuticals for patients 

Business location Germany and regulatory and economic framework 

for research, development and production of biopharmaceutical 

Biosimilars 

Orphan medicinal products (medicines for rare diseases) 

Advanced therapies such as gene and cell therapy and tissue 

engineering products 

Bild: © vfa / Martin Joppen



Till Erdmann 

Managing Director Myelo Therapeutics GmbH 

Dirk Pleimes 

Managing Director and Chief Medical Officer 

Myelo Therapeutics GmbH 

But they will only do so if the general conditions for venture capital 

are significantly improved. The political decision makers seem to 

agree on this objective – now all they have to do is adopt relevant 

new laws. 

The Start-Up Capital is Booming 

For many years, the Berlin-Brandenburg region has been generating 

international headlines as the start-up capital of Germany. 

Hardly a week goes by without a new start-up being founded, a 

major financing round being concluded or a major corporation 

committing to act as an accelerator or incubator. The region is 

booming; it’s an international hot spot. However, this has more to 

do with IT and web-based applications start-ups. 

We are a young pharmaceutical company that develops new 

therapies in fields of application with high medical needs. With 

a clear strategy for developing our innovative active ingredient 

Myelo001 for treating chemotherapy-induced neutropenia, we 

have successfully obtained the support of a series of strategic 

investors, including IBB Beteiligungsgesellschaft, Eckert Life 

Science Accelerator (ELSA) and Valenta Pharmaceuticals. 

The German capital region provides a high concentration of 

science and research, clinics and business, as well as a high 

quality of life. It is predestined to be a location for pharmaceutical 

companies. The technology parks and networks that 

are part of the Healthcare Industries cluster represent an outstanding 

infrastructure for translating the latest scientific findings 

into innovative products. 

210 

200 

190 

180 

170 

160 

150 

140 

Market Segments of Companies 

204 

88% 

130 

120 

110 

100 

90 

80 

70 

Number of companies 

60 

50 

40 

30 

20 

10 

31 

14% 

45 

19% 

0 

'04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 

Agriculture/Food 

White Biotechnology /Environmental Biotechnology 

Biomedicine 

Most companies focus on biomedicine. A total of 88 % of companies, focus primarily on development in the areas of new diagnostics, drug development 

and associated services or technologies. 13 % of the companies are active in the agriculture / food sector, white biotechnology / environmental 

biotechnology amounts to 19 % of all entries. (Source: Internal survey, BioTOP database, responses from 232 companies, multiple entries, February 2014) 

10

AAT TGA CAC ACG TTC GCC GAT AAG GAA GTT ATG GAA CCT 

GGA CCA TCA CGA TAA AAC GGA CAA TTA CCC GAT TGG AAA 

ATC GAA ACC GAA TCA GCC AGT CAA GAA GCT TTC GAC TGC 

GTA TTG CAA GGC CAC CAG TAG CAC ACG TGC GGA ACG ACA 

TAA ACT GGA ACA AGA TCC AAA GCT TAT TGG AAG TGC CCG 

CCA STudieS & ConSulTinG GCA TAC CAA TGC ATG CAC GGA 

AGG TTC GTA TTA ACT AGA GAT CAT TCT AAC CCT TAT AGC 

GTT ConferenCeS AAG GAG ATC CCC TTG ACC GGC CGG T TT 

TCC CTC CTG GCG GTG TCA AAT CAG TGA CGA CCG TGT ACA 

ACA BookSTC TCG CCA TAA CGT TGG CTT AAA GCT TAG GCC 

GCC ACG GAA ACG GGT GAC GGG AAT CCA ACC GAC AGA ATT 

TGA TV & VideoAC TCC GCA CAT TTG CGA GCT AGA ACG TAA 

GCC TAG GCT CAA AAC GCA TGT GCC GAT CAA GAA TGC AAG 

GAT CorporATe puBliShinG T TT GGA GAA CTA ACA TCT AGA 

ATC CAG CTT ACC AGA TGC AAG ATC TTG GGA GGC ACT GAG 

GTA inTerneT CTC CGC ACG TCC AAT GGA ATC GTA TAA CCA 

AGG GTT TCC ACA GCC TGA GCC GAT ATC GTA AGG TGA CAA 

GAA MAGAzineSGA TTC GTC CTC AGT ACG TCA TAG CAA ACT 

CAC TCA ACC CAA GGA GTT GTA CTA CTG CGC GAA CTT ACG 

CGA eVenT MAnAGeMenT TA GCG TCG ACG CAC CAA TGC ACC 

GCC AAC GCC CAG TCC ATT AGA GAG TCA TAA GAC GCA GCA 

CAA CAC GCT GTT CCC GGA TGC ACA GCC AGG ACT CTT TGC 

AGC GGC AAA GCA CAT CCA AGA GAA TGG GAC ACG TGC CAC 

ACC GGC GCA TGT TGA CAC AAT CAG CCT GAT TAG CAC CAG 

TAA GCT AGA CAA ACA TCT We CreATe knoW ledG e ! TGG 

AGT G TT CTC AAG GAA TGA CGA TGT GCC TTG ACC TCG ACG 

GTT ACT ACG TCC TGC ATG TTG CGA TTG GGA AGA AAA CTC 

BIOCOM AG | Lützowstraße 33–36 | 10785 Berlin | Germany 

www.biocom.de | Tel. +49 (0)30 264921-0 | Fax +49 (0)30 264921-11



Does this status relate at all to start-ups in the life sciences? At first 

glance, perhaps not. But take a closer look: The large number of 

players (founders, investors and incubators), the university support 

programs and many start-up competitions, and the range of 

various activities create a start-up-compatible atmosphere, which 

has a positive impact on the start-up scene in the life sciences. 

Putting it simply, the spillover effect is high. 

There have not been as many life sciences start-ups in years as 

there were in the last half of fiscal year 2013/2014. And the striking 

thing about them is that some of the new companies are focusing 

on new drug development. Here are a few examples of recent 

start-ups and their concepts: 

OMEICOS Therapeutics is a spin-off of the Max Delbrück Center 

for Molecular Medicine. It develops synthetic compounds with 

Our Business: Committed to Improving Health 

12 

For more than 230 years, Takeda has been serving society 

with innovative medicines. Now, with new healthcare solutions 

from prevention to care and cure, we are determined to help 

even more people enjoy their lives to the fullest. Of our 30,000 

employees worldwide, 1,700 are working in Germany to 

develop, produce and market a broad range of medicines to 

help patients reclaim valuable moments of life from illness. 

innovative modes of action for the treatment of various human 

diseases. The company is working on a new drug for the treatment 

of atrial fibrillation, the most common type of human cardiac 

arrhythmia. Myelo Therapeutics has developed a drug for 

the prophylactic treatment of post-chemotherapy patients whose 

blood contains too few white blood cells (neutropenia) or platelets 

(thrombocytopenia). Venture capital investors IBB Beteiligungsgesellschaft 

with their VC Fonds Technologie Berlin, Eckert Wagniskapital 

und Frühphasenfinanzierung and JSC Valenta Pharmaceuticals 

are in the company’s financing consortium. Amal 

Therapeutics, a company with facilities in Geneva and Berlin, is 

developing a vaccine consisting of a recombinant protein with a 

cell-penetrating peptide acting as a vector. The unique property 

of this platform is its ability to trigger a highly integrated, multi-epitopic 

cellular immune response to cancer cells. DexLeChem, a 

TU Berlin spin-off, provides development services to the chemiwww.takeda.de



Financing and Added Value 

Venture Capital 

for companies in Berlin 

cal-pharmaceutical industries for making production processes 

more chiral, meaning to convert substances with spatially complex 

designs into water-based processes. The catalyst is not modified 

before re-use. With this resource-conserving reaction process 

control, customers – drug and fragrance manufacturers – benefit 

from more cost-efficient, environmentally friendly production processes. 

GlycoUniverse is a technology spin-off of the Max Planck 

Institute of Colloids and Interfaces. The company specializes in 

the automated development and synthetic production of complex 

sugars. With GlycoUniverse’s state-of-the-art oligosaccharide 

synthesizer GLYCONEER ® , the process of synthesizing complex 

carbohydrates that formerly took months or years can be completed 

in a matter of days or even hours. 

The high number of start-ups is the result of a critical mass of 

players, activities and initiatives in the start-up area, its welldeveloped 

infrastructure and excellent location factors as 

well. These include the seven biotechnology parks that make 

affordable laboratories and technical infrastructure available, 

and the many scientific institutes that produce highly skilled 

specialists. The universities join in with comprehensive spin-off 

support programs, some of which are triggered by the federal 

government’s “EXIST-Gründungskultur - Die Gründerhochschule” 

competition. Pharmaceuticals giant Bayer Healthcare has 

also discovered the region’s potential, providing the technical 

infrastructure, professional support and expertise of an 

established pharmaceuticals company to young companies via 

its CoLaborator, opened in May. Another important element is the 

many business plan competitions in which founders receive initial 

feedback for their business concepts. With 140 events, a network 

of over 200 consultants and over 500 business plan submissions 

per year, the Berlin-Brandenburg Business Plan Competition is 

one of the largest competitions of this type in Germany. 

IBB Beteiligungsgesellschaft mbH offers equity financing 

for high tech companies in Berlin. For our fund 

VC Fonds Technologie Berlin (€52m) we are looking 

for investment opportunities in the biotechnology and 

medical technology sector. 

Our investment approach is based on hands-on involvement 

and active management support for each 

portfolio company, delivered by our highly experienced 

investment team. VC Fonds Technologie Berlin 

not only provides capital, but also helps execute the 

business plan. 

Are you interested? Please do not hesitate to contact us. 

IBB Beteiligungsgesellschaft mbH 

Mrs. Ute Mercker / Mr. Christian Seegers 

Bundesallee 210 

10719 Berlin / Germany 

Phone: +49 (0)30 2125-3201 

www.ibb-bet.de 

The momentum in the Berlin-Brandenburg region is powerful – 

especially at the interface of IT and the life sciences. There are 

a variety of names for this new area, including eHealth, itHealth, 

dHealth and mHealth. What they all designate is the successful fusion 

of the two fields, facilitated by web-based applications in the 

medical sector. This development is still young, but with its unique 

density of IT and life sciences players, the Berlin-Brandenburg 

location is particularly suitable for generating new companies. 

The first companies have already been founded; take Caterna, an 

online school for visual exercises, or NeuroNation, the new digital 

brain-jogging platform for example. There are many new companies 

in this new field, and in XL Health, it even has a financially 

strong investor specialized in digital health. 

Selected portfolio companies: 

VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank 

Berlin (IBB) and the State of Berlin. It is co-financed by the European Regional 

Development Fund (ERDF). 

13


BioTOP-Report Pharma 

Pharma 

Attractive Location 

The capital region has developed into one of Germany’s most important, attractive centers for the medical and 

healthcare industries. Based on the significant growth of the pharmaceuticals industry in Berlin, these sectors are 

the growth engine of the regional industry. Currently, the sectors employ approx. 10,000 people in the German 

capital region. This means that pharmaceuticals companies account for around one in every 10 jobs in the regional 

industry – and every 11th employee in the pharmaceuticals sector in German works in Berlin. 

Above all, the sectors benefit from the capital region’s excellent 

scientific environment and clinical research landscape, the proximity 

to decision-makers in the healthcare system and the ready 

availability of well-educated skilled specialists. A steadily growing 

number of global players and medium-sized companies are setting 

up business here or moving their corporate headquarters to 

Berlin and the capital region, to take advantage of these location 

assets. With over 220 companies, Berlin is also a leading global 

location in the biotechnology sector and the pharmaceuticals industry 

has created a close, innovative network with these partners. 

The Berlin-Brandenburg region has an outstanding position in several 

sectors that the experts certify as having a strong growth 

outlook due to their excellence in innovation. 

The pharmaceuticals sector's innovative excellence pays doubly 

for Berlin-Brandenburg, which is also one of the country's leading 

research locations. The partnership between pharmaceuticals 

companies, clinics and hospitals and scientific institutions guarantees 

ultra modern patient healthcare of a uniquely high quality, 

and the innovations of the pharmaceuticals companies are creating 

and securing the jobs of the future for the region. 

The current investment and activities of the local pharmaceuticals 

sector are proof of Berlin's appeal and bear witness to the 

companies' commitment to the capital region. Bayer has paid 

billions to conclude the takeover of Norwegian cancer treatment 

specialists Algeta. Bayer made the move to strengthen its position 

in the tumor medication area. The company is also increasing its 

commitment to young, innovative technology companies. In May 

2014, it launched the CoLaborator incubator program. An incubator 

model for biotechnology start-ups, CoLaborator was tested 

in San Francisco (Mission Bay) two years ago. In the specially 

equipped research building, up to 10 innovative biotechnology 

companies can now get to work – thanks to Bayer. 

Globally active corporations are located along the Spree River: 

Bayer Healthcare, Berlin-Chemie, Pfizer Deutschland, Sanofi 

Deutschland and since 2011, Takeda. The capital region is also 

home to over 20 medium-sized pharmaceuticals companies, including 

several world market leaders. 

Within the next two years, Berlin-Chemie will invest €40 million in 

the expansion of its location, continuing to develop its position as 

one of the sector's leading employers. 

Dr. Rainer Uppenkamp 

CEO Berlin-Chemie AG 

In Berlin, we find an excellent scientific and commercial environment. 

This is an important basis for further investments and 

the expansion of our location in the south-east of the city. In 

addition required extensions are planned, among others a new 

building for the quality control, a new staff canteen, an extension 

of the office capacity for the administrative area and the 

resulting infrastructural measures in the form of new roads, 

paths and parking facilities for our employees. 

14

You need commitment, focus and 

passion to find new ways to fight the 

diseases of this world: innovation 

is at the heart of it. 

Innovation for better health. Our commitment 

is to bring to patients around the world quality 

medicines for use in diag nosing, combating and 

preventing disease. Every day we work against time, 

researching new pathways, new molecules, new 

technologies – complementing our own capabilities 

with exper tise of innovative partners from science 

and industry. 

The success of this work is evidenced in new 

m e d i c i n e sforareaswithsignificantunmetmedicalneed 

such as oncology, cardiovascular and blood 

diseases, as well as gynecology and ophthalmology. 

Our aim is a better quality of life for all. 

www.bayerhealthcare.com 

www.bayerpharma.com


BioTOP-Report Pharma 

Alfonso Casal 

CEO 

PharmaMar GmbH 

Our presence in Germany, the European State Member with 

the largest population in the EU and strong research capabilities 

is an important step in our European expansion. From 

our offices in Berlin we coordinate our commercial operations 

as well as supporting other corporate activities in Germany. 

Berlin as Capital city, with important competence centers for 

the treatment of cancer and strong international orientation 

represents a very good opportunity for the development of our 

activities. 

The partnership between Sanofi and Charité that began in May 

2010 with a focus on the area of stroke research has proven fruitful. 

The partners have signed an agreement to a second joint 

research partnership, this time with a focus on diabetes. The 

scientists and clinicians of both parties will also collaborate in a 

diabetes alliance in the future. The alliance aims to improve understanding 

of the medical requirements and approaches to the 

disease of diabetes and, in joint projects, to implement them as 

therapies and make them available to patients more quickly. 

After the acquisition of Nycomed in 2011, Takeda moved its German 

headquarters to Berlin and took over the Oranienburg-based 

production plant. Oranienburg has a long tradition as a location for 

pharmaceuticals production. In the past 20 years, the plant there 

has expanded continuously. It now has a production capacity of 

7.6 billion pills and capsules per year – 98 percent of which are 

exported worldwide. The Oranienburg facility is considered one 

of the main competence centers within Takeda's global production 

network. Takeda plans to expand the Oranienburg facility's 

production capacity within the next few years. 

An important new player, Teva Specialty Medicines, has recently 

set up business in Berlin. Newly founded Teva Specialty Medicines 

is Teva Pharmaceuticals' Original Products division in Berlin. 

Its primary area of success is neurology. Teva is the leader in 

generics in Germany and an expert in innovative brand business. 

At a January 2014 press conference in Berlin, Aristo Pharma presented 

a new formulation of a proven drug for treating severe and 

extreme pain. The special formlulation was designed for targeted 

retardation and 24-hour continuous analgesia when taken once a 

day. Founded in 2008, the company belongs to a growing group 

of German companies headquartered in Berlin. 

DR. KADE acquired Takeda’s OTC business for the German market 

in April 2013. With this move, the traditional Berlin company 

has added well-known brands to its current OTC portfolio and 

made an investment in the future. In conjunction with the expansion 

of its OTC business, the company has added new employees 

in its Berlin and Constance locations. 

PharmaMar is a Spanish member of the Zeltia Group, a leader in 

the development of anti-tumor drugs of marine origin. PharmaMar 

started its activities in Germany in 2007, when the EMA granted 

it marketing authorization for Yondelis ® in the treatment of soft tissue 

sarcomas. Two years later, Yondelis ® was approved for the 

treatment of ovarian cancer. In 2013, the company established 

PharmaMar GmbH in Berlin. 

These current examples are only an indication of the pharmaceuticals 

industry activity in Berlin-Brandenburg – but they illustrate 

the extent to which the opportunities here are multi-faceted. They 

range from close partnerships with regional biotechnology startups 

and partnerships with science to location expansion and 

inward investment. The range of opportunities and the strategic 

options they generate make the Berlin-Brandenburg region highly 

attractive. 

Dr. Hans-Christian Meyer 

Site Manager 

Takeda Plant Oranienburg 

Pharmaceutical development and production has a long tradition 

in the area of Berlin-Brandenburg. The roots of our production 

plant in Oranienburg trace back to the 19th century. 

Today, our site plays a pivotal role as a competence center for 

solid forms such as tablets and capsules within the worldwide 

pharmaceutical production network of Takeda. The support 

of the Investitionsbank des Landes Brandenburg helps us to 

further expand production capabilities, be prepared for future 

growth and create new jobs. 

16

We – for the life 

Modern research, development and manufacturing 

of innovative medicines in Berlin-Adlershof – this is 

what BERLIN-CHEMIE stands for. Research and 

production are based not only on our experience of 

over one hundred years but also on our successful 

search for new therapeutic pathways and possibilities. 

The success we have gained around the world 

and the growth of BERLIN-CHEMIE are an endorsement 

of our high standards. 

For more information: 

BERLIN-CHEMIE AG · Glienicker Weg 125 ·12489 Berlin 

Phone: +49 30 6707-0 ·www.berlin-chemie.de


BioTOP-Report Glycoscience 

Glycoscience 

Glyco Research for Innovations in Health Industry 

Alongside genome and proteome research, the study of sugars glycoscience, is increasingly gaining importance. 

As our knowledge about the function of sugar structures in a variety of biological processes grows, the areas of 

application for glycoscience are also growing and affecting other fields in the Healthcare Industries cluster such as 

diagnostics, drug development, regenerative medicine and industrial biotechnology. Sugars can develop complex 

structures, glycans, and can be even bound to proteins – in which case they are called glycoproteins. Glycans 

are important for a wide variety of biological processes. They control cell-cell communication and the function and 

stability of proteins, and play an important role in the immune response. Carbohydrate metabolism malfunctions 

are typically associated with neurodegenerative diseases, infections and cancer. 

Exploiting high potential for interdisciplinary 

technologies 

Glycan structures, as molecules expressed due to illness, can 

be used as significant diagnostic parameters and can serve as 

differentiation markers for regenerative medicine. Glycan-based 

molecules can also be used as vaccines e.g. for malaria and HIV. 

Glycoscience also contributes to the development of drugs, innovative 

foods and human-compatible biomaterials. When considering 

the diverse application fields of glycoscience, it is apparent 

that the capital region occupies an outstanding position. 

Berlin-Brandenburg is a technology leader in the chemical synthesis 

of glycans, and in glycan analytics it offers internationally 

significant expertise. We also provide excellent conditions for 

applications in the fields with high cross-innovation potential. The 

region is a leading international location for research and development 

in diagnostics and the implementation of clinical studies 

and also has highly productive drug and nutrition research. With 

the university hospital Charité Universitätsmedizin Berlin globally 

acknowledged medical expertise is also present in the region. 

growth period in recent years and the acquisition of €55 million 

in venture capital, Glycotope now has over 180 employees and 

is a world leader in glycobiotechnology. The objective is to turn 

Berlin-Brandenburg into a leading international center for glycoscience 

research and translation for the development of diagnostic 

and pharmaceutical products, cell-based therapies and new 

materials for medical applications by employing an expansion 

strategy. We will also be working to intensify the technology transfer 

based on regional networks and stabilize the communication 

between science and industry. 

GlycanForum, the international conference that takes place in Berlin 

every year, presents the current status and outlook for glycoscience 

in biomedicine. It is organized with the support of the Center 

for Molecular Diagnostics and Bioanalysis (ZMDB) and BioTOP 

Berlin-Brandenburg. The most important conference in the world 

with regard to glycoscience, GlycanForum is an outstanding open 

exchange platform for business, industry and users. With a subtheme 

of "The leading scientists of Asia," the 7th conference in 

2013 was focused on the topics of healthcare, material science, 

analytics and synthesis. 

Establishing a glyco hub in the capital region 

Research, whether university-related, independent or clinical, 

forms the outstanding scientific basis of the region. The Charité 

has been honing its expertise in the fields of glycoanalytics and 

glycodesign for many years. The director of the Max Planck Institute 

of Colloids and Interfaces in Potsdam (MPIKG) and internationally 

renowned glycoscientist Professor Peter Seeberger 

discovered and developed the total synthesis of complex carbohydrates. 

GlykoUniverse, a spin-off company, will distribute the 

completely automated carbohydrate synthesizer. There are other 

excellent companies in the region as well. Located in Berlin, Scienion 

GmbH is distinguished in the field of glycan microarray technology 

for molecular diagnostics. Glycotope GmbH is specialized 

in optimizing sugar structures of glycoproteins and developing 

therapeutic antibodies for cancer cells. In the wake of a strong 

Dr. Véronique Blanchard 

Head of Glycoanalytics working group 

at the Institute of Laboratory Medicine, 

Clinical Chemistry and Pathobiochemistry, 

Charité – Universitätsmedizin Berlin 

As a location for glycoscience, the capital region is unique in 

Europe. You find the entire spectrum here, from basic research 

to manufacturing industry, which creates the ideal conditions 

for efficiently translating research innovations to industry and 

clinics. At Charité, we are researching the potential of glycanbased 

biomarkers in tumor diagnostics and in bioanalytics for 

the quality assurance of stem cell preparation, and developing 

a glycan microarray platform for diagnostics. 

18

Corporate Finance Consulting for Life Science Companies 

With more than 15 years of experience, Portus 

Corporate Finance supports technology focused 

companies in all areas of financing. We base our work 

on solid know-how, years of experience and reliable 

business partners. 

Portus Corporate Finance GmbH 

Friedrichstr. 81 

D-10117 Berlin 

Tel (030) 700 800 900 

Fax (030) 700 800 901 

Email info@PortusCo.com 

www.PortusCo.com 

If you are looking for advise and support in the 

areas of 

• Company and Project Funding 

• Company Succession / M&A 

• Finance Management / CFO-Services 

• Consulting and Coaching 

• Establishment of Businesses 

please don‘t hesitate to contact us! 

UHY Deutschland AG is a joint venture of long established 

auditing and consulting firms with a total of 250 employees 

and partners. 

As a member of UHY International, a global association of 

independent accounting and consulting firms with over 

7,600 employees, we can provide audit, accounting, tax 

and consulting services in 275 business centres across the 

globe. 

UHY Deutschland AG has extensive experience in financial 

and consulting services for life sciences companies for 

many years. 

We offer the following services: 

•• 

Audits of financial and consolidated statements 

under the German Commercial Code (HGB) and IFRS 

•• 

Accounting & Reporting 

•• 

Due diligence (financial and tax) and business valuations 

•• 

Consulting services on IPOs 

•• 

Business Advisory 

•• 

Mergers & Acquisitions (M&A) 

•• 

German and international taxation 

We have offices in Berlin/Bremen/Cologne/Frankfurt/Hamburg/Munich/Stuttgart 

For further information please contact Dr. Ulla Peters 

UHY Deutschland AG · Wirtschaftsprüfungsgesellschaft · Zimmerstraße 23 · 10969 Berlin 

Phone +49 30 226593-0 · Fax +49 30 22679050 · www.uhy-deutschland.de · www.uhy.com


BioTOP-Report Bioelectronics 

Bioelectronics 

The Joint Lab Bioelectronics – 

A New Platform for the Integration of 

Microelectronics into Life Sciences 

The introduction of new experimental techniques causes a major advantage in the field of biology. Well-known 

examples are the invention of optical and electron microscopy, without which the fundamental structures of life as 

cells and cell organelles could not have been discovered. The next paradigm shift may very well be triggered by 

applying microelectronics – and its developing field of bioelectronics – at its interdisciplinary interface with the life 

sciences. 

This positive outlook is mainly a result of the phenomenon called 

“scaling” in microelectronics: for the last few decades, minimum 

feature dimensions have continuously become smaller by a factor 

of around two every second year. At first glance, this seems 

to be a minor development relating to an uninteresting technical 

parameter, since we have become accustomed to working with 

increasingly powerful computers and to storing higher and higher 

data volumes on a single flash memory. For the life sciences, however, 

scaling is a major advance. It has taken microelectronics or 

more accurately, nanoelectronics, to the same structural levels at 

which the molecular mechanisms of life operate. 

Particularly interesting perspectives arise for biosensorics, in 

which semiconductor preparation technology can be applied to 

the fabrication of cost-effective diagnostic systems. Bioelectronics 

is also significant for the process analytical techniques (PAT) 

for monitoring, regulating and increasing the efficiency of bioprocesses. 

The Berlin-Brandenburg region is eager to take advantage 

of this development and therefore, IHP in Frankfurt (Oder) 

and the TU Berlin Institute of Biotechnology have founded Joint 

Lab Bioelectronics. This step will intensify the interdisciplinary exchange 

between the two disciplines and expand biotechnology 

students’ knowledge of the basics of microelectronics. 

Prof. Dr. Peter Neubauer 

Technische Universität Berlin 

Institute for Biotechnology 

Chair for Bioprocess Engineering 

The Joint Lab Bioelectronics aims to advance the field of Bio- 

Process Analytical Technologies by connecting sensor specialists 

and bioengineers. 

JANUARY 2013 

Charité and FU are jointly successful in the competition "EXIST-Gründungskultur 

– Die Gründerhochschule" of the German Federal Ministry of Economics and 

Technology +++ German Research Foundation extends collaborative research 

centre (SBF 650) at Charité – ten million Euros for research on immunological 

therapy 

FEBRUARY 2013 

Humboldt research award gets Ivy-League professor Klaas van Wijk to Potsdam 

+++ Biopolymers – strong future field with high potential for innovation presents 

itself in Schorfheide 

MARCH 2013 

Hasso-Plattner-Institut speeds up personalised medicine with new data bank 

technology +++ Integrative Research Institute for Life Sciences (IRI) founded in 

Berlin +++ Paul Ehrlich- and Ludwig Darmstaedter Prize goes to MDC scientist 

Dr. James Poulet 

APRIL 2013 

Charité and Sorbonne found Virchow-Villermé Centre for Public Health +++ EU- 

OPENSCREEN included in the new BMBF-roadmap for large research infrastructures 

MAY 2013 

New laboratory building of MDC opened – named after physiologist Max Rubner 

+++ Stem cell researchers in Germany pool their expertise. They found the German 

Stem Cell Network (GSCN) on May 7 th 2013 +++ Evaluators praise Berlin 

Institute of Health (BIH). Enst Theodor Rietschel becomes chairman 

JUNE 13 

BIH officially opened +++ Charité – Universitätsmedizin Berlin once more reaches 

rank 1 of Focus-ranking "Germany's best hospital" 

JULY 2013 

Prof. Angelika Eggert receives Einstein professorship and takes over as head of 

the Children's Clinic with focal areas of oncology and hematology +++ Scientists 

from the A*STAR Genome Institute Singapore and the Max Planck Institute 

for Molecular Genetics (MPIMG) in Berlin decode the communication network in 

human embryonic stem cells +++ Scientists from Charité and the MDC, working 

in cooperation with colleagues in Kiel, Boston, Zurich and London, discover a 

new gene for hereditary heart failure +++ Scientists working with Peter Seeberger 

(MPIKG) in Potsdam-Golm have developed a simple, cheap and reliable test for 

Yersinia pestis, the bacteria that caused the plague 

AUGUST 2013 

1000th protein structure decoded at BESSY II +++ The World Health Summit 2013 

in Berlin in August 2013 discussed solutions for global healthcare with regard to 

“Research and Innovation.” +++ BPI and vfa present national plans of action for 

the quick diagnosis and more effective treatment of rare diseases 

SEPTEMBER 2013 

Scientists at Charité and MDC discover sugar withdrawal as an innovative cancer 

therapy approach +++ Technische Universität Berlin and Leibniz Institute IHP 

Frankfurt (Oder) have established Joint Lab Bioelectronics, a laboratory for joint 

interdisciplinary research +++ Charité and Harvard sign a cooperation agreement 

aimed at accelerating clinical translation, primarily in the cell and tissue 

technology field +++ Prof. Annette Grüters-Kieslich, Charité Dean, receives the 

20



PD Dr. Mario Birkholz 

Head of Joint Lab Bioelectronics 

IHP GmbH 

Leibniz-Institut für innovative Mikroelektronik 

By establishing the IHP and TUB Joint Lab Bioelectronics, we 

have created the opportunity for a successful interdisciplinary 

partnership. Through it, we will be able to translate the progress 

made in microelectronics directly into biotechnological 

applications and university education. 

The Leibniz Institute IHP – Innovations for High Performance 

Micro electronics – in Frankfurt (Oder) is part of the Leibniz 

Association and has a long tradition in the area of silicon-based 

microelectronics. The IHP has a clean room at its disposal for the 

pilot serial production of 200-mm Si wafers in which microchips 

are processed at the 0.25 and 0.13 µm structure levels. A family of 

SiGe: C-based hetero bipolar transistors for realizing frequencies 

in the low 100 GHz range is the core of IHP technology. As part 

of IHP’s multi-project wafer services, external customers may use 

the technology for the fabrication of application-specific integrated 

circuits. 

The TU Bioprocess Engineering chair conducts research on the 

characterization of industrial-scale bioprocesses and methods for 

consistent, faster bioprocess development. The chair runs a bioprocess 

pilot plant with advanced analytical instruments, on-line 

instrumentation and an analytical laboratory for comprehensive 

metabolomics analysis. Its key instruments are proprietary, scaledown 

two- and three-compartment bioreactors, which enable the 

simulation of large-scale industrial processes in the lab. The characterization 

of biogas plants, brewery reactors and reactors in 

industrial biotechnology with new PAT and model-based process 

control for improving their robustness are a major focus. For this 

highest honor offered by ESPE, the European Society for Paediatric Endocrinology: 

the Andrea Prader Award +++ New Helmholtz post-graduate school for 

researching biomaterials opens 

OCTOBER 2013 

Fraunhofer researchers receive an international award for ArtCornea ® , their 

artificial cornea +++ The capital has healthcare in focus: Berlin Health Week 

celebrates its launch +++ Sanofi endows two new professorships in the public 

health field at Centre Virchow-Villermé, the newly established German-French 

research institute, in its Berlin and Paris locations +++ Charité opens the intensive 

care station of the future 

NOVEMBER 2013 

NeuroProAllianz receives Technical University of Applied Sciences Wildau 

research award Dr. Jean-Yves +++ K. Tano from the University of Toledo arrives 

in Berlin after receiving an Alexander von Humboldt fellowship +++ Charité 

coordinates the national network of biobanks +++ Immunologist Prof. Klaus 

Rajewsky from MDC Berlin awarded the Society for Signal Transduction medal 

of honor 

DECEMBER 2013 

Charité opens pioneering robotics operating room +++ Scientists from Charité 

present new approaches toward improving breast cancer therapy as part of 

the RESPONSIFY EU research project 

JANUARY 2014 

Under the leadership of Cornelia Weikert from the German Institute of Human 

Nutrition (DIfE), a team of scientists has discovered a new biomarker for heart 

failure in the general population +++ Researchers at MDC Berlin have acquired 

new knowledge of the body's regulation of insulin production for insulin resistance, 

the root of type 2 diabetes +++ The biochemist and protein crystallographer 

Prof. Oliver Daumke from MDC Berlin-Buch receives European Research 

Council funding worth millions +++ BTU Cottbus-Senftenberg strengthens biomaterials 

research network with Helmholtz Center Geesthacht in Teltow 

FEBRUARY 2014 

MPIKGPotsdam director Prof. Peter Seeberger and the director of the NII in 

New Dehli, India agree to intensify their partnership for researching infectious 

diseases +++ Researchers at MDC decipher the creation of new forms 

of hereditary Alzheimer’s disease and discover new protective mechanisms 

+++ Researchers at the Max Planck Institute for Moldcular Plant Physiology in 

Potsdam-Golm discover new adapter proteins for the reception of substances 

in plant cellss +++ The Berlin Institute of Health (BIG) acquires Thomas Südhof, 

Noble Prize for medicine co-awardee, as visiting fellow 

MARCH 2014 

Two dozen Fraunhofer Society institutes establish the Big Data Alliance +++ 

MDC receives 3-Tesla MRI scanner for the largest long-term German population 

study +++ MDC researchers discover the molecular switch for epilepsy 

APRIL 2014 

Berlin Institute for Health Research launches first research projects +++ Hans- 

Hilger Ropers awarded with the “EURORDIS Scientific Award 2014” for his 

research on rare diseases 

21



purpose, new lance- and rope-based mobile sensor and sampling 

systems that can be directly applied to analyze concentration 

gradients have been developed. 

A robot-based mini pilot plant has also been established for process 

development in micro-plate and mini-bioreactor cultures. 

This highly automated facility focuses on processes with genetically 

engineered microorganisms. Extensive analyses are automatically 

performed on tens to hundreds of cultivations in μl 

and ml formats. The laboratory pioneered the EnBase ® controlled 

substrate delivery technology, which is instrumental for consistent 

bioprocess development and a key element in this high-throughput 

(HT) automated industrial reference laboratory. 

Joint Lab Bioelectronics’ mission is to introduce new biosensor 

technologies. This work focuses on the adaption of the sensor 

system to the particular biotech application. The starting point is 

the sensor chips developed at IHP, including a fully embedded 

microelectromechanical system (MEMS) for affinity assays and a 

cell sensor operated via impedance spectroscopy (see Fig. 1). 

However, the biochips fabricated in semiconductor fabs require 

special packaging before being introduced into bioprocesses 

with an emphasis on hermiticity and must be shielded against 

corrosion from the liquid bio milieu. 

switching time t sw (ms) 

150 

140 

130 

120 

110 

100 

90 

80 

30º 

35º 

40º 

T dependence of t sw 

in sensoric fluid 

for varying c g 

glucose concentration c g (mM) 

Figure 1. Affinity-viscosimetric microsensor chip with fully embedded 

MEMS (X-shaped beams on the left) und calibration curves for glucose 

concentration measurements it has taken, Birkholz et al., J. Appl. Phys. 113 

(2013) 244904. 

The demand for microsensors for applications in microfluidic 

platforms has jumped in recent years. Many applications rely on 

polymer devices, because most companies and scientific working 

groups have almost no access to microelectronic fabrication 

techniques. Joint Lab Bioelectronics follows the approach of developing 

and supplying biotechnological platform modules that 

combine equal shares of microelectronic and microfluidic components. 

Bioprocess engineering is one promising field of application for 

miniaturized sensors. Industrial bioprocess development faces 

the challenge of reducing the risks, costs and timeframe of new 

product launch. In the pharmaceuticals industry in particular, the 

regulatory authorities expect dossiers to be based on knowledge 

that derives from careful sensing (PAT). Consequently, future bioprocess 

development will consist of HT technologies based on 

miniaturizing, parallelization, automation and intense monitoring. 

Joint Lab Bioelectronics is a perfect match for the Bioprocess 

Engineering chair’s HT lab, where platform technologies are developed 

to comply with the above-mentioned needs. This lab is 

Joint Lab Bioelectronics – miniaturized sensors 

EnBase ® 

Robotics 

MagReSyn TM 

DoE 

Sensors 

Integration 

Fed-batched in μl 

and mL scale 

Automated 

cultivation 

Automated DSP 

and analytics 

Experimental 

plans, modelling 

On-line 

data reading 

Automated 

data evaluation 

Figure 2. Steps in consistent, automated bioprocess development based on process analytical technologies, experimental design approaches and the early 

consideration of the industrial process by applying the fed-batch mode. 

22



able to screen volumes of as little as 200 µl per vessel, in up 

to 96 vessels at the same time. Process development and production 

process characterization take place simultaneously, in up 

to 48 miniaturized stirred-tank bioreactors with a working volume 

of approx. 10 ml. The cultivation, process analytics and product 

recovery processes are automated with the help of a liquid handling 

system (lab robot). In close collaboration with Joint Lab Bioelectronics, 

the scientists explore the application and integration 

of microsensors for glucose concentration and cell density in HT 

systems. The overall process development approach relies on 

consistency: experimental planning determines parameter fields, 

production systems are investigated under process-related conditions 

and IT tools handle data. These platform technologies are 

currently being applied to specific demonstrator processes. Interested 

customers can also take advantage of the HT lab’s services. 

Last but not least, Joint Lab Bioelectronics aims to teach microelectronics 

to Biotechnology students, since the job markets of 

the the future will demand large numbers of graduates specialized 

in this field. The “Introduction to Bioelectronics” course was 

introduced in 2012 and has been held every summer semester 

since then. It was recently included as a mandatory elective 

course in the Master of Biotechnology program at TU Berlin. 

For the second year in a row, Joint Lab Bioelectronics will organize 

a bioelectronics symposium in September 2014, where leading 

experts in the field will discuss their recent developments. IHP will 

present its biotechnology-relevant technology modules during the 

second day of the symposium. We cordially invite interested colleagues 

from the life sciences and microelectronics to participate 

in the symposium. 

Achieve innovation, 

shape the future 

Start shot for young technology companies 

High Tech Gruenderfonds is your partner for Seed Stage investing. We 

help out young, high potential startups in the early phases of technology 

and product development, as well as successful launching. Our assistance 

is not limited to our cash investments, instead we strive to add long term 

added-value to portfolio companies through our extensive network of 

professional and our accredited coaches. 

High-Tech Gründerfonds Management GmbH 

Software 

Internet & Telecommunication 

Media & E-commerce 

Life Science 

Materials Science 

Nanotechnology & Chemistry 

Energy 

Automation 

Photonics 

Industrial Software 

Schlegelstraße 2 | 53113 Bonn 

Phone: +49 (0)228-823001-00 | Fax: +49 (0)228-823000-50 

E-Mail: info@htgf.de 

http://www.high-tech-gruenderfonds.de 

INVESTORS OF HIGH-TECH GRUENDERFONDS II 

23

BioTOPics 47 | 6. Juni 2014 (3:02) 

BioTOP-Report Business Location 

Business Location 

Excellent Services for Berlin-Brandenburg 

The Berlin-Brandenburg region harbors outstanding potential for technological development and cooperation in its 

high-density landscape of scientific and research institutions. The high concentration of international excellence 

here facilitates interdisciplinary exchange, making it easier to realize new, landmark developments. At the same 

time, the sheer number of players can make it difficult to find the right partner. The region’s Inward Investment and 

Expansion team supports the healthcare and life sciences sectors with a full range of services, including marketing 

activities at national and international trade shows. Our team has been in direct contact with the region’s companies 

and scientific institutions for many years and can provide quick access to the right contacts and potential partners. 

In 2013, Berlin Partner for Business and Technology supported 

expansion projects and provided location services to 33 companies 

in Berlin, generating around 320 new jobs and a projected 

investment of €63.9 million within the next three years. The list of 

companies includes Cell Medica, CBR Biotech Strategies, Amal 

Therapeutics and G&Life, an Italian company. 

As in previous years, we organized a Berlin-Brandenburg Night 

to mark the opening day of the BIO conference and exhibition 

in Chicago. Once again, Bayer HealthCare was the lead sponsor. 

Accepting the invitation from HealthCapital and Bayer HealthCare, 

around 400 international guests from biotechnology and pharmaceutical 

companies attended the event. 

In the same year, the Brandenburg Economic Development Board 

(ZAB) supported approx. 130 investment and innovation projects 

in the healthcare sector with a total investment volume of around 

€27 m and the potential to create 220 new jobs. The successful 

location of technology-based start-ups such as Glyco Universe, 

ai-ibiomics and medneo deserves special mention. The team 

at ZAB also supported the expansion investments of resident 

companies co.don and Seramun. With the aim of positioning 

the region’s companies in the global markets and presenting the 

Berlin-Brandenburg Healthcare Industries cluster – HealthCapital 

– as one of Europe‘s leading healthcare sector locations, the 

region exhibited at four important international fairs in 2013. 

Dr. Rainer Knaus 

Senior Vice President 

Cell Medica Ltd. 

Cell Medica, a leading T-cell therapeutics company and pioneer 

in the field, acknowledges the importance of the German 

market and especially the excellent conditions in Berlin. 

The European commercial manufacturing facility within the 

Campus Berlin-Buch biotechnology park was designed and 

equipped to facilitate the high quality GMP-compliant production 

of patient-specific cell therapies for distribution across 

Europe. Here in Berlin, we have found an outstanding scientific 

and industrial environment that allows us to attract highly 

educated, well-trained personnel who are keen to help shape 

this new era of cell-based therapeutics. 

To provide support in the areas of internationalisation, technology 

transfer and regulatory affairs to companies and scientific institutes 

already located in Berlin and Brandenburg, we organized more 

than 30 conferences, workshops and networking events last year. 

The 2,000 accredited participants came from all over Germany. 

Berlin-Brandenburg is also a life sciences hot spot for international 

delegations. At the 2013 BIONNALE, our annual biotechnology 

conference, a group from Denmark presented its products and 

services and networked with representatives from regional companies 

and scientific institutions. 

In 2013, we kicked off the first “Health Week” for the capital region. 

Companies and organisations from the healthcare industries 

took advantage of the opportunity to showcase their prevention, 

diagnostics and therapy expertise and services. Over 90 companies 

and institutions organized more than 300 public events in 

one week. 

Carolin Clement 

Head of Unit Biotech I Pharma 

Berlin Partner for Business and Technology 

Phone +49 30 46302-430 

carolin.clement@berlin-partner.de 

www.berlin-partner.de 

Dr. Ute Hartmann 

Head of Department Healthcare Industry/ Life Sciences 

Brandenburg Economic Development Board (ZAB) 

Phone +49 331 20029-250 

ute.hartmann@zab-brandenburg.de 

www.zab-brandenburg.de 

24

Life Sciences. 

Living Research. 

Berlin. Brandenburg. 

A vibrant network. 

Berlin-Brandenburg is one of Europe´s leading locations for the 

Life Sciences. It is also an R&D capital that magnetically attracts 

the world´s top scientists. Here you´ll find attractive funding 

conditions, close linkages between business and science, the 

highest concentration of R&D in Europe, a dynamic startup scene 

and a multifaceted entrepreneurial environment made up of more 

than 500 pharmaceutical, biotech and medical technology 

companies. Come discover this one-of-a-kind landscape for 

scientists and entrepreneurs. 

www.healthcapital.de


BioTOP-Report Spotlight on European Business and Internationalization 

Spotlight on European Business and Internationalization 

The Enterprise Europe Network Berlin-Brandenburg 

The Healthcare Industries cluster Berlin-Brandenburg has been an active member in a variety of European networks 

and initiatives for many years. With the launch of Horizon 2020, the new EU research funding program, one network 

in particular has taken center stage: the Enterprise Europe Network (EEN) Berlin-Brandenburg. With 20 experts on 

Europe from the three participating host organizations Berlin Partner for Business and Technology, Brandenburg 

Economic Development Board (ZAB) and the East Brandenburg Chamber of Commerce and Industry, it is the basis 

for internationalization in the region – primarily for small and medium-sized companies. 

Helping SMEs find business and technology partners throughout 

Europe, the EEN provides information and advice on the innovation-oriented 

developments, initiatives and programs of the European 

Union. The EU Commission initiated the network, which 

connects 100 regional consortia in approx. 60 countries in Europe 

and the world to each other, at the beginning of 2008. Over 500 

regional economic development institutions, chambers of industry 

and commerce and technology agencies with a total of 4,000 

employees collaborate closely within the network. Supporting 

small business is a cornerstone of the EU's drive for growth and 

jobs: 99% of all companies in the EU are small and medium-sized 

(SMEs) and they account for 67% of the jobs. The EEN’s services 

are tailored to SMEs, but are also available to all other businesses, 

universities and research centers. 

Services tailored to small companies 

Taking part in an EU-funded research project is a great way to 

boost a company's competitiveness. SMEs need the right partners 

for successful projects, and the Enterprise Europe Network helps 

by identifying companies' needs and potential and connecting 

them with each other. The network does not fund any projects itself, 

but helps companies to tap into the EU's funding opportunities. 

Horizon 2020 leads the way – it is the EU's latest research funding 

program, launched in December 2013 with a volume of almost 

€80 billion. Normally, its consortia must consist of companies from 

three different EU countries, but the EEN also assists SMEs with 

this aspect. The network’s business cooperation database is one 

of the world's largest and contains thousands of company profiles. 

Companies can meet potential business partners in person 

at EEN’s matchmaking events, which often take place at international 

fairs to help keep travel and accommodation costs low. 

For example, the Enterprise Europe Network Berlin-Brandenburg 

played a major role in opening up the annual BIONNALE – the key 

biotechnology and pharmaceutical industry meeting place in the 

capital region – to an international audience. Almost 80 participants, 

including a larger company delegation from partner country 

Denmark, gathered for the matchmaking event EEN organized 

in 2013. On the day of BIONNALE 2013, the participants held 

around 160 meetings. 

The regional EEN contact point for all themes relating to the 

healthcare industries: 

Wolfgang Korek 

Project manager EEN Healthcare Industries 

Phone +49 30 46302-518 

wolfgang.korek@berlin-partner.de 

www.berlin-partner.de 

Elias Zafirakos 

Science & Innovation Network Manager 

Biopeople Københavns Universitet 

The matchmaking session organized by the Enterprise Europe 

Network gave the Danish delegation a valuable opportunity 

to meet with potential German collaboration partners at the 

Bionnale 2013. The EEN setup made it possible to plan and 

book meeting ahead of the conference and was a great help in 

exposing the Danish Delegation towards the German audience. 

Dajana Pefestorff 

Project manager International Business 

Director EEN 

Phone +49 331 660-3234 

dajana.pefestorff@zab-brandenburg.de 

www.zab-brandenburg.de 

26



Alacris Theranostics GmbH 

Alacris Theranostics GmbH is a Berlin-based 

company with the mission to exploit next generation 

sequencing and other omics data 

through its predictive modelling system Mod- 

CellTM for drug development and personalised 

medicine in oncology. This approach 

was originally developed at the Max Planck 

Institute for Molecular Genetics in Berlin and 

is exclusively licensed to Alacris. 

Unlocking The Power Of 

Individualised Medicine 

Alacris provides extensive bioinformatics 

expertise and well equipped facilities including 

a next generation sequencing lab for 

clinical application and a powerful IT infrastructure. 

Alacris works together with clinics 

and industry leaders in the fields of personalised 

medicine, biomarker application, and 

drug development. 

With its proprietary ModCell System, 

Alacris Theranostics applies a new, revolutionary 

systems biology modelling approach 

to better match patients to therapies and 

therapies to patients. ModCell provides a 

'Virtual Patient' model allowing predictive 

analysis of cancer patient samples on therapy 

outcome. ModCell integrates next generation 

sequencing derived genome and 

transcriptome information with a generic cancer 

model of molecular processes in tumour 

onset and progression. ModCell facilitates 

the simulation of the effects of different 

drugs for the development of new personalized 

medicine approaches in the clinic and 

for effective development and approval of 

drugs for the pharmaceutical industry in 'Virtual 

Clinical Trials'. 

Address 


Fabeckstraße 60-62 

Phone +49 30 84312250 

14195 Berlin · Germany 

info@alacris.de 

www.alacris.de 

co.don AG 

The biopharmaceutical company based near 

Berlin is one of the leading specialists worldwide 

in cell cultivation for the regenerative 

treatment of articular cartilage defects and 

spinal disc defects. In many cases the use of 

the company's patented pharmaceutical 

product can avert the need for joint and spinal 

disc replacement surgery. Orthopaedic, 

accident and neuro-surgeons are increasingly 

applying these regenerative treatment 

methods. co.don ® AG manufactures cellbased 

tissue engineering therapeutics to the 

highest quality standards. Its products represent 

a revolutionary pro cess in the biological 

replacement of dam aged articular cartilage 

and invertebral disc by building up strictly 

autologous tis sue without the involvement of 

any external carrier materials or additives. 

The applica tion of the products may be minimally 

inva sive or arthroscopic and so surgery 

and reha bilitation times are significantly 

reduced for both doc tor and patient. Because 

no external materi als are used, the risks of 

rejection, inflamma tion and infection are 

reduced to the minimum. co.don ® AG is certified 

in accordance with DIN EN ISO 

9001:2008. Furthermore, pro duction, quality 

control and quality assur ance have been certified 

in accordance with European Guidelines 

for Good Manufactur ing Practice (EU- 

GMP). co.don ® AG‘s technological, production 

and regulatory expertise makes the company 

a first mover in the market for biological 

carti lage and disc tissue replacement and a 

provider of highly effective, safe treatment 

options not only resulting in relief of pain, but 

actual repair of damaged tissue. 

co.don ® AG is listed on the Frankfurt Stock 

Exchange (ISIN: DE000A1K0227). 

Address 

co.don AG 

Warthestraße21 

14513 Teltow · Germany 

Contact 

Matthias Meißner, M.A. 

Head Corporate Communications/IR/PR 

Phone +49 3328 4346 0 

Fax +49 3328 4346 43 

info@codon.de · www.codon.de 

27



Evestra GmbH 

Evestra GmbH, founded in July 2008, is a 

fully owned subsidiary of Evestra Inc. located 

in San Antonio Texas. Evestra GmbH serves 

as the development and commercialization 

center for Europe and ROW. Evestra’s mission 

is to develop and commercialize steroidbased 

female healthcare products. The 

development strategy of the company 

includes product ideas with known compounds 

as well as New Chemical Entities. 

Evestra is conducting research and product 

development in a number of in-demand, but 

as yet unmet, medical need areas of women’s 

health such as hormonal-dependent 

breast cancer and endometriosis. The company 

is also pursuing different projects in 

fertility control, e.g. a new estrogen for oral 

contraception, with superior pharmacological 

properties compared to the standard 

drug ethinyl estradiol. 

Address 

Evestra GmbH 

Britzer Straße 26 


EU Contact 

Prof. Klaus Nickisch · Managing Director 

Phone +49 30 66509642 

knickisch@evestra.com 

www.evestra.com 

Several patents on new composition of matter, 

new technical processes and use patents 

have been filed during the last years and 

support the strong intellectually property 

position. Evestra is concentrating on R&D 

and will seek more partners for commercialization. 

More detailed information can be found on 

our website. 

LGC Genomics 

At LGC we offer a full range of high quality 

PCR reagents, custom genotyping assays, 

genomic services and workflow solutions for 

DNA sample preparation and downstream 

processing (www.lgcgroup.com/genomics). 

Our proprietary KASP allelic discrimination 

chemistry and has optimised workflows for 

1536 microtitre plates that enable assay miniaturisation 

for more flexible, cost-effective 

workflow solutions in high-throughput genotyping. 

In addition, customers are offered 

industry leading proprietary nucleic acid 

extraction, sequencing and genotyping services 

from our labs globally. 

„We use what we sell and sell what we use” 

is key to the products and services we provide. 

Our portfolio includes: 

kkGenotyping services, assays and 

reagents 

kkSanger and next-generation sequencing 

services 

kk 

DNA and RNA extraction products and 

services 

kk 

PCR reagents and consumables 

kk 

Laboratory instrumentation 

kk 

Plate sealers 

kk 

Liquid handling robots 

kk 

High-throughput PCR thermal cyclers 

kk 

Plate readers 

We operate sales offices in the UK, Germany 

and the USA, with sales representatives 

throughout Europe, the USA and Australia as 

well as distributors in China, Korea and other 

key emerging territories. 

Address 

LGC Genomics GmbH 

Ostendstrasse 25 · TGS Haus 8 


Phone +49 30 53042200 

genomics@lgcgroup.com 

www.lgcgroup.com/genomics 

28



Metanomics Health GmbH 

Metanomics Health – a BASF Group company 

– combines comprehensive Metabolite 

Profiling (metabolomics) with biomedical 

data interpretation. Metabolite Profiling is 

defined as the parallel analysis of multiple 

endogenous and xenobiotic metabolites in 

biological systems. The core expertise of 

Metanomics Health resides in discovery and 

validation of biomarkers. 

Technologies 

kk 

Metabolite profiling platform with more 

than 75 GC-MS and LC-MS/MS instruments 

kkWide metabolite coverage via combination 

of unbiased and targeted platforms 

kkUnique tox mode of action prediction 

through MetaMap ® Tox database 

kk 

Excellence in systems correlation analysis 

of complex gene function relationships 

kk 

Highly robust and reproducible results 

Major R&D-Topics 

In cooperation with academic institutes and 

clinical experts Metanomics Health is running 

a large-scale diagnostic biomarker program. 

Areas include metabolic syndrome, 

heart failure, prostate cancer and pancreatic 

cancer to mention a few. 

Market Segments 

Metanomics Health provides its services to 

pharmaceutical, diagnostics and nutrition 

companies. Technology applications include: 

kk 

Mechanism of action studies 

kk 

Mechanism of toxicity studies 

kkTranslational and clinical biomarker 

development (e.g. PK/PD, patient stratification, 

efficacy and safety markers) 

kkCompanion diagnostic development 

kkCell culture & bioprocess optimization 

kk 

Biospecimen quality control 

Address 


Tegeler Weg 33 · 10589 Berlin · Germany 

Contact 

Dr. Tim Bölke · Managing Director 

Phone +49 30 34807 400 

Fax +49 30 34807 401 

company.info@metanomics-health.de 

www.metanomics-health.de 

nanoPET Pharma GmbH 

nanoPET is a biopharmaceutical company 

specialized on R&D, manufacturing and marketing 

of innovative drug substances for 

Diagnostic Imaging. We focus on relevant 

cardiovascular, oncological and neurological 

indications as well as on regenerative medicine. 

Nanotechnology is a key element of our 

business. We operate in three major areas. 

The first nanoparticular tracers for clinical 

PET: nanoPET prepares the clinical development 

of its patented technology platform: 

inorganic nanoparticular tracers for cell- and 

molecular-specific positron emission tomography 

(PET). 

Viscover imaging agents – a landmark in 

small animal imaging: As animal imaging is 

rapidly gaining relevance in pharmaceutical 

research, we are delighted to offer you an 

exciting portfolio of specialized pre-clinical 

imaging agents covering the principal imaging 

modalities (MRI, CT, Ultrasound, Optical 

Imaging, SPECT & PET). Get a detailed 

insight into our product portfolio and download 

a free copy of our imaging guide on 

www.viscover.com 

long-standing industry expertise our team 

has attained in the pharmaceutical 

research & development. 

Address 


Robert-Koch-Platz 4 


Contact 

Dr. Andreas Briel · CEO 

Phone +49 30 890 49740 

imaging@nanopet-pharma.com 

www.nanopet-pharma.com 

Consulting and Service tailored to your 

needs: As a technology and service provider, 

we offer our expertise to biopharmaceutical 

companies and imaging equipment manufacturers. 

Our customers benefit from the 

29



Getting your innovation going. 

Our tailored financing are your key to success. Our consultants look forward to meeting you. 

Contact us: 

Phone: +49 (0)30 / 2125-4747 

E-mail: wachsen@ibb.de 

www.ibb.de/wachsen 

140305_IBBanz_biotop12_210x148.indd 1 05.03.14 12:22 

ORGANOBALANCE GmbH 

Exploring and managing microbial 

biodiversity 

ORGANOBALANCE explores the potential of 

probiotic bacteria and yeasts for new product 

developments in food, feed, personal 

care, and for the pharmaceutical industry or 

the production of fine chemicals. From a 

large collection of microorganisms, specific 

strains are selected to e.g. inactivate pathogens, 

produce new bioactives, neutralize 

malodorous or toxic substances and synthesize 

high titers of valuable compounds. 

ORGANOBALANCE draws on natural 

resources, which are gathered in the company-owned 

collection of 8000+ microbial 

strains, mostly originating from foodstuffs. 

ORGANOBALANCE uses its OASSYS ® bioassays 

for highly efficient screenings. The platform 

allows to quickly identify the most suitable 

strains from the microbial collection for 

targeted applications. 

ORGANOBALANCE has a broad expertise in 

the field of yeast metabolic engineering. This 

includes designing and developing new production 

strains for industrial biotechnology 

applications. Specific strains of Saccharomyces 

cerevisiae, which carry engineered biosynthesis 

pathways for the environmentally 

friendly production of carboxylic acids, terpenoids, 

steroids and other lipid compounds 

are available. 

ORGANOBALANCE works in collaboration 

with partners and grants licenses for own 

product developments. 

Address 


Gustav-Meyer-Allee 25 


Contact 

Dr. Christine Lang · CEO 

Phone +49 30 46307200 

Fax +49 30 46307210 

info@organobalance.com 

www.organobalance.com 

30



syneed medidata GmbH 

Are you getting the whole picture? 

We Do. 

syneed medidata GmbH is an independent, 

privately owned contract research organization 

(CRO) providing end-to-end services for 

phase I to phase IV clinical trials and for noninterventional 

studies. Commencing business 

in 1985, we have constantly expanded 

our service portfolio. In 1995 we conducted 

our first medical device study, and in the 

same year we started our Imaging Core Lab 

operations (see below). Moreover, we offer 

the complete scope of Pharmacovigilance 

services for development projects as well as 

for marketed products (drugs and medical 

devices). Our notion of service is based on 

the knowledge that every project is unique – 

and that custom-tailored solutions serve best. 

This is reflected in all our actions. As an 

example, for data capture our clients may 

choose between paper and different EDC 

solutions, including our proprietary EDC system, 

which has been developed for multinational 

non-interventional studies and gets 

enthusiastic feedback from both customers 

and end-users. syneed medidata GmbH 

combines experience with the quality, dedication 

and flexibility of a midsized organization. 

Full clinical and biometric services 

for clinical trials and non-interventional 

studies 

Operational services offered in EU, CEE, 

Russia and USA through our established 

alliance of partner CROs 

Very high staff retention - stable, 

experienced teams delivering projects 

on time and with highest quality 

Pharmacovigilance and Imaging services 

for development projects and marketed 

products 

Best value for money due to 

tailor-made services 

So, for almost any trial you can think of, we 

provide the expertise you need for turning 

data into results. 

Address 

syneed medidata GmbH 

Cicerostraße 21 


Phone +49 30 31172751 00 

www.medidata.de 

info@medidata.de 

Contact 

Dr. Christian Hucke 

Clinical Program Director 

christian.hucke@medidata.de 

syneed imaging 

syneed imaging, the Medical Imaging Core 

Lab of syneed medidata GmbH, offers solutions 

for study planning, protocol development, 

site evaluation, image collection and 

processing and conduct of central independent 

reviews with a wide variety of criteria 

(e.g. RECIST, 1.0 and 1.1, Choi, Cheson, irRC, 

RANO, PERCIST, mRECIST). 

Within almost 20 years of operation we have 

managed trials in various indications (oncology, 

neurology, radiology, PET diagnostics, 

devices) and modalities, and established an 

extensive network of medical experts who 

support us as consultants and independent 

readers. Our experience, flexibility and pricing 

especially for early phase trials are highly 

valued by Biotech clients. 

All study data are hosted solely in Germany 

on our servers maintained by own IT staff. 

Address 

syneed imaging & syneed medidata GmbH 

Cicerostraße 21 


Phone +49 30 31172751 00 

Contact 

John Uiters 

Director Medical Imaging Services 

john.uiters@medidata.de 

31



Bioparks 

Networks 

Scientific Institutions 

P Companies 

Biotech Networks 

kkBioTOP Berlin-Brandenburg 

kkBioHyTec Network for Biohybrid Technologies 

kkBioResponse 

kkCenter for Molecular Diagnostics and Bioanalytics (ZMDB) 

kkDiagnostikNet-BB 

kkNetwork Glycobiotechology Berlin-Brandenburg 

kkRegenerative Medicines Initiative Berlin-Brandenburg 

kkRiNA Network for RNA Technologies 

Scientific Institutions 

kkBerlin-Brandenburg Center for Regenerative Therapies (BCRT) 

kkBrandenburg University of Technology (BTU) 

kkCharité – Universitätsmedizin Berlin 

kkFraunhofer Institute for Applied Polymer Research (IAP) 

kkFraunhofer Institute for Biomedical Engineering (IBMT) 

kkFreie Universität Berlin (FU) 

kkGerman Heart Instiute Berlin (DHZB) 

kkGerman Institute of Human Nutrition (DIfE) 

kkGerman Rheumatism Research Center (DRFZ) 

kkHumboldt-Universität zu Berlin (HU) 

kkInstitute of Biomaterial Sciences, Helmholtz-Zentrum Geesthacht 

(Teltow) 

kkLausitz University of Applied Sciences 

kkLeibniz-Institute for Agricultural Engineering Potsdam-Bornim 

(ATB) 

kkLeibniz-Institut für Molekulare Pharmakologie (FMP) 

kkLeibniz-Zentrum für Agrarlandschaftsforschung (ZALF) e. V. 

kkMax Delbrück Center for Molecular Medicine (MDC) Berlin-Buch 

kkMax-Planck-Institute for Colloids and Interfaces 

kkMax Planck Institute for Infection Biology 

kkMax Planck Institute for Molecular Genetics 

kkMax Planck Institute of Molecular Plant Physiology 

kkRobert Koch Institute 

kkTechnische Universität Berlin (TU) 

kkUniversity of Applied Sciences Berlin (HTW) 

kkUniversity of Applied Sciences Wildau 

kkUniversity of Potsdam 

32



IFHI 

33


BioTOP-Report Biotech Parks 

Biotech Parks 

The BioCampus Network Berlin-Brandenburg 

Berlin-Brandenburg boasts seven biotechnology parks, which offer optimal space for the specific requirements 

of every company. This geographic concentration of specific biotech parks is unique in Germany and probably 

in all of Europe. The parks differ in their offers and strategic focus and provide ideal conditions for newcomers. 

More than half of the 232 companies are currently utilizing the infrastructure of a publicly or privately managed 

park. In addition, the young companies benefit from the closeness to science and the permanent contact and 

exchange. 

berlinbiotechpark 

In the very heart of Berlin 

berlinbiotechpark Management GmbH · Herr Frank Elsner 

Max-Dohrn-Straße 8–10 · 10589 Berlin 

Phone +49 30 20364205 · Fax +49 30 20364190 

info@berlinbiotechpark.de · www.berlinbiotechpark.de 

berlinbiotechpark is located on a 86,000 sq.m. site in the 

very heart of Berlin, currently offering a total of approx. 

63,000 sq.m. of office, laboratory and production space, with 

a building potential for another 45,000 sq.m. of rental area. 

The site, which is home to Biotech/Pharma/Service Companies 

is supplied with a complete range of media for laboratory 

and production purposes, with production steam with possibility 

to upgrade to HP steam, power supply, compressed-air, 

nitrogen and other inert gases, cooling water and DI-water , all 

being provided at favorables rates. 

The infrastructure includes conference facilities as well as 

works security and waste disposal services. It is rounded off 

by production-related services such as plant engineers and 

laboratory technicians, industrial safety engineers, a medical 

service as well as best-buy services and communication services. 

Offering flexible growth potential, production-orientated 

media equipment and comprehensive industrial-specific 

services and infrastructure, berlinbiotechpark is particularly 

attractive for growing internationally orientated technology 

companies. Furthermore, it offers a permanent base in Berlin 

for developing companies that have outgrown the size allowed 

by their limited start-up funding. The inner-city location and 

the excellent public transport guarantee short ways to all scientific 

institutions and hospitals of the city. 

Biotech Campus Potsdam 

Research on the Waterfront 


Steinstraße 104-106 · 14480 Potsdam 

Phone +49 331 6601628 · Fax +49 331 6601699 

info@biotechcampus.de · www.biotechcampus.de 

Contact: Gabriele Ziegler 

Just a few minutes away from Potsdam’s central railway station 

in the direction of Caputh, Biotech Campus Potsdam 

is located on the Hermannswerder peninsula in the river 

Havel. It is owned and operated by Biotech Campus Potsdam 

GmbH, a fully owned subsidiary of the Investment Bank 

of the State of Brandenburg. 

34



The biotechnology center is housed in four buildings dating 

from around 1,900 and one modern complex and offers a 

total of 11,400 sq.m. of laboratory, office, greenhouse and 

storage space. With such a large facility at its disposal, it offers 

biotechnology companies an ideal environment for successful 

operations. All labs are approved as S1 laboratories 

and meet the building requirements for approval as S2 labs. 

The Hermannswerder site also includes an S3 laboratory as a 

special resource. The beautiful, park-like setting of the peninsula 

offers an excellent environment for research activities. 

The island hotel and a conference center are located directly 

next to the campus. 

The site also includes a self-service restaurant and small island 

shop. The philosophy of Biotech Campus Potsdam was, 

and still is, to create the freedom for research and innovation 

in the high-tech sector of biotechnology. Reputable firms from 

the industry can indeed be found here. 

Biotechnology Park Luckenwalde 

Space for Expansion 

Biotechnologiepark Luckenwalde · c/o SWFG mbH 

Im Biotechnologiepark, TGZ I · 14943 Luckenwalde 

Phone +49 3371 681100 · Fax +49 3371 681105 

bio-luck@swfg.de · www.bio-luck.de 

Contact: Dipl.-Ing. Christoph Weber · Director 

Located just 25 miles from the new Berlin-Brandenburg International 

Airport (BBI) in the district of Teltow-Flaeming, 

the Biotechnology Park Luckenwalde is one of the most 

modern facilities of its kind in Germany. It is home to 35 

companies from Germany, USA, UK, Korea and Israel with 

about 500 employees. 

The work carried out by resident companies is multi-faceted, 

ranging from green biotechnology, the development of vaccines, 

the development of pharmacologically active substances 

based on plant materials, the development and production 

of PCR tests for food testing and preclinical contract research 

right through to medical technology. A total of 200 employees 

work on the site. 

Companies in the park focus on the development and production 

of pharmaceuticals, recombinant proteins and diagnostic 

kits, biological/chemical substances for biotech and pharmaceutical 

applications, as well as fine chemicals. There are also 

suppliers of medical technology, analytical services, and a 

Biotech Education Center. Technical Equipment comprises 

completely furnished S2 laboratories (safety workbench, autoclave, 

dishwasher, deionized water, water purification system, 

central media supply (compressed air, N 2 

, CO 2 

, O 2 

, H 2 

), storage 

and cool rooms, pharmaceutical clean rooms category 

35



(B/C), 400 MHz NMR spectrometer, meeting rooms, conference 

hall (300 seats), library, restaurant with catering service. 

start-up funding, we additionally hold 80,000 sq.m. developed 

industrial property ready for expansion. 

The entire central technique meets GMP/ISO 9001 specifications. 

The park management offers comprehensive, individual 

services and advice during the settlement and development 

of firms, including support for the recruitment of the key staff. 

Currently the park offers 9,000 sq.m. labs and office space, 

and additional 100,000 sq.m. industrial property ready for 

expansion. The park is part of an international and regional 

network to assure access regional and to funding sources and 

cooperation with universities and hospitals. 

Co:bios Technologiezentrum 

Service for all stages of growth and expansion 

co:bios Technologiezentrum GmbH 

Neuendorfstraße 20 a · 16761 Hennigsdorf 

Phone +49 3302 2021250 · Fax +49 3302 2021257 

info@cobios-technologiezentrum.de 

www.cobios-technologiezentrum.de 

Located in the northwest of Berlin, the co:bios Technology 

Center in Hennigsdorf is the congested urban area in Berlin-Brandenburg 

of biotechnology and life science. In the last 

15 years more than 30 companies with approximately 700 

international employees have settled on this site. 

With our holistic approach combining settlement, development, 

construction and licensing issues to the point of traditional 

management consulting, and on the background of the high 

density of innovative, research-intensive and service-oriented 

companies on the co:bios biotechnology park Hennigsdorf 

we can initiate interesting synergy effects for your business 

model. Within this locational advantages the co:bios biotechnology 

park became a magnet for the international healthcare 

industry and the percentage of international settlements on 

this site is growing, for example from USA, South America, 

VAI and Asia. 

Campus Berlin-Buch 

Interaction of Research, Clinics and Companies 

On more than 10,000 sq.m. we offer service space for 

extension to clean rooms (class D/E/F), S1 labs, DI-water supply, 

compressed air supply, special gas supply, state of the 

art data communication, meeting rooms, conference hall and 

more. The building and central technique requirements also 

meet the fulfillments for S2 labs for GMP/ISO 9001 based production 

specifications. As a center of excellence for biotechnology 

and life science we have a selected portfolio of service 

and advice to young start-ups as well as medium sized companies, 

in aim to support them across all stages of company 

growth. For those companies who have outgrown their limited 

Robert-Rössle-Straße 10 · 13125 Berlin 

Phone +49 30 94892511 · Fax +49 30 94893812 

info@bbb-berlin.de · www.bbb-berlin.de 

Contact: Dr. Andreas Mätzold · Executive Manager 

Dr. Ulrich Scheller · Executive Manager 

36



Berlin-Buch is the location of one of the largest biotechnology 

parks in Germany, with 31,000 square meters of scalable 

lab and office space for start-ups and maturing companies. 

Situated to the northeast of the city, the Berlin-Buch Campus 

is currently home to 56 companies, 41 of which are biotech 

companies; the rest provides support services. 

Berlin Adlershof 

Germany’s leading Science- and Technology 

Park 

Beside the BiotechPark the Max Delbrück Center for Molecular 

Medicine, the Leibniz Institute for Molecular Pharmacology 

as well as clinical groups from the Charité University Hospital 

within the Experimental and Clinical Research Center are 

part of the Campus community. The Campus gives access to 

high-end technology platforms, state of the art infrastructure, 

interdisciplinary communication, projects and expertise in a 

wide range of items, especially in translational research. The 

BiotechPark at the Campus Berlin-Buch offers: 

Adlershof Zentren für Biotechnologie und Umwelt 

WISTA-MANAGEMENT GMBH 

Rudower Chaussee 17 · 12489 Berlin 

Phone +49 30 63922221 · Fax +49 30 63922212 

terytze@wista.de · www.adlershof.de 

Contact: Heidrun Terytze 

Head of Center for Biotechnology and Environment 

kk 

Immediately available lab and office space 

kk 

Excellent research and clinical expertise on-site 

kkTraining programs for personnel on spot 

kk 

An international community of like-minded people 

kk 

Interdisciplinary networks and platforms 

Berlin Adlershof focuses on photonics and optical technologies, 

material and microsystems technology, information 

and media technology, as well as biological, and environmental 

technology. There are currently 25 biotech companies 

in Adlershof occupying 18,200 sq.m. of lab and office 

space. The companies focus on: 

The BiotechPark including the Innovation and Incubation Center 

is managed by BBB Management GmbH Campus Berlin-Buch. 

Acting as a full-service company BBB’s main tasks 

are the settlement, accompanying and support of Biotech 

businesses. 

kkBiotechnology products and procedures development 

kkPharmaceutics, medicine, and medicine technology 

kkAnalytics 

kkEnvironmental technology 

Technical Equipment comprises laboratories with a basic 

equipment: security-lockers, laboratory basins, work benches, 

vacuum supply, preliminary setup for supply of pure gases 

and compressed air, reconfiguration for further media and 

gases, central cooling, preliminary setup for cold water supply 

37



in rental areas, refitting of heat exchanger by the tenant possible. 

Adlershof. Science at Work. 

Science Park Potsdam-Golm 

Connecting Excellence 

The GO:IN Innovation Center offers young technology-based 

companies and entrepreneurs a range of office and laboratory 

spaces along with extensive services and optimal support 

for a successful market launch. Close proximity to the other 

players at Potsdam-Golm and the intensive networking of the 

different institutions and companies here offer perfect conditions 

for the development and exploitation of synergies. 

Standortmanagement Golm GmbH 

Am Mühlenberg 11 · 14476 Potsdam-Golm 

Phone +49 331 237351130 

www.wissenschaftspark-potsdam.de · www.goin-potsdam.de 

Contact: Friedrich W. Winskowski · Managing Director 

Science Park Potsdam-Golm combines cutting-edge 

international research and the training of young scientists 

in a high-powered location in the immediate vicinity of the 

German capital Berlin. Alongside the Faculty of Science and 

the Human Sciences Faculty of the University of Potsdam, 

three Institutes of the Max Planck and two of the Fraunhofer 

Society as well as an innovation center with currently 

22 companies operate in Brandenburg’s largest science park. 

More than 2,500 people work at Potsdam-Golm and more 

than 9,000 students are pursuing their academic qualifications 

here. The pleasant and very family-friendly working environment 

on the edge of a nature conservation area, the high 

quality of life in and around Potsdam and continuous growth 

make Potsdam-Golm a highly attractive location. Professional 

site management is extending the park infrastructure and 

fosters the integration of the capabilities and interests of 

all institutions, associations and companies that operate at 

Science Park Potsdam-Golm. 

38


BioTOP-Report Addresses 

Addresses 

Addresses 

Networks 40 

Biotech Parks 40 

Other Parks 41 

IP Asset Management 41 

Universities and Research Centers 41 

Banks and VCs 41 

Supporting Organisations 42 

Pharmaceutical Companies 42 

Contract Manufacturers 44 

Contract Research Organisations 44 

Biotech Companies 46 

For Companies on the Rise 

Equity Financing – building 

on your strengths! 

Are you looking to expand your business and maximize on growth prospects 

in the technology sector in Germany? Yet, you require some support and 

equity financing to get your project successfully underway in a new marketplace? 

Then, we are the right partner for you! 

We pride ourselves in providing the best in equity financing to our 150 corporate 

clients totalling over 150 million in strategic financing. We are dedicated 

to assisting our customers to advance their businesses in new areas and to 

enable sustainable growth of business and even greater success. 

Remember, your success is our success. Let us be part of your success story! 

Contact us now. 

Foto: ILB 

www.ilb.de



Networks 

BioHyTec – Verein für Bioanalytik 

und Biohybrid-Technologien e. V. 

BioResponseNetzwerk 

DiagnostikNet-BB Netzwerk 

Diagnostik Berlin-Brandenburg 

Health Capital Berlin- 

Brandenburg 

Regenerative Medicine Initiative 

Berlin-Brandenburg 

RiNA -Netzwerk RNA- 

Technologien 

Zentrum für Molekulare 

Diagnostik und Bioanalytik 

BioHyTec is the biohybrid technology network in the life sciences cluster of Berlin-Brandenburg. 

This new field of technology is the interface between biosensor development 

and microsystems technology. Biohybrid systems open up new applications in pharmaceutical 

research, clinical diagnostics, food analysis and genetic engineering. 

BioResponse is an interdisciplinary research and development organisation with members 

from Brandenburg, Berlin and Saxony. It focuses on the development and marketing 

of multiplex assays for diagnostic antibody identification based on the proprietary 

BioResponse technology, which is comprised of fully automated image analysis of fluorescence-encoded 

microparticles and labelled cell structures. 

DiagnostikNet-BB is the Berlin-Brandenburg network for in vitro-diagnostics. Members 

include biotech companies as well research institutes and clinics. Main objectives of 

the network are: Development of system solutions, optimizing compatibility, close cooperation 

with leading clinicians and joint marketing. 

In order to develop the scientific and economic position of the region, the governments 

of the states of Berlin and Brandenburg have put the master plan “Healthregion Berlin 

Brandenburg” into effect. Its key to a continued success is a continued close interplay 

between research, development and education7vocational training with production, 

application and supply. All of these activities are integrated and coordinated through 

the Network “Gesundheitswirtschaft Berlin Brandenburg” under the brand of “Health- 

Capital”. 

The mission of the RMIB is to promote the Berlin-Brandenburg region as a center of 

excellence for Regenerative Medicine particularly for cell-based medical biotechnology. 

The RMIB promotes networking in the field and supports the further development of 

clinical studies and education programs. The initiative fosters the collaboration between 

universities, research institutes, companies (including SMEs) and organizations in the 

field of science and technology. 

The RNA-Network provides ongoing support and funding for the development of RNA 

technologies with the goal to commercialize the results. One main focus is the improvement 

and application of the RNA interference technology. Further projects develop RNA 

aptamers, cell-free protein biosynthesis systems and analyse the structure and function 

of RNA molecules. The RiNA RNA-Network encourages co-operation and information 

exchange between academy and industry. 

The Centre for Molecular Diagnostics and Bioanalytics (ZMDB) is a virtual centre operated 

under the auspices of the Fraunhofer Institute for Biomedical Technology and 

the Charité – Universitätsmedizin Berlin in close cooperation with the region’s company 

networks. The aim is to bring together regional expertise in basic research, technology 

development, clinical research and industrial cooperation initiatives to set up joint projects 

that will speed up the development of in vitro-diagnostics “Made in Berlin-Brandenburg”. 

biohytec.de 

bioresponse.de 

diagnostiknet-bb.de 

healthcapital.de 

rmib.de 

rna-network.com 

zmdb.de 

Biotech Parks 

berlinbiotechpark 


berlinbiotechpark is located on a 86,000 m² site in the very heart of Berlin, currently 

offering a total of approx. 57,000 m² of office, laboratory and production space, with 

a building potential for another 45,000 m² of rental area. Offering flexible growth potential, 

production-orientated media equipment and comprehensive industrial-specific 

services and infrastructure, berlinbiotechpark is particularly attractive for growing internationally 

orientated technology companies. 

Just a few minutes away from Potsdam’s central railway station in the direction of Caputh, 

BIOTECH CAMPUS POTSDAM is located on the Hermannswerder peninsula in 

the river Havel. It is owned and operated by BIOTECH CAMPUS POTSDAM GmbH, a 

fully owned subsidiary of the Investment Bank of the State of Brandenburg. 

Biotechnologiepark Luckenwalde Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg International 

Airport in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde 

is one of the most modern facilities of its kind in Germany. It is home to 35 companies 

with about 500 employees from Germany, USA, UK, Korea, and Israel. 

Co:bios Technologiezentrum 

GmbH 

Campus Berlin-Buch bbb 

Management GmbH 

Adlershof Zentren für 

Biotechnologie und Umwelt 

The co:bios Technology Center in Hennigsdorf offers affordable rental opportunities 

and a selected portfolio of services and advice to young start-ups as well as medium-sized 

companies. Therefore Hennigsdorf is a center of excellence for life sciences, 

especially in the field of red biotechnology and medical technology. 

Berlin-Buch is home to one of the largest biotechnology parks in Germany, with 26.000 

square meters of scalable lab and office space for start-ups and maturing companies. 

Situated to the northeast of the city, the campus is currently home to 56 companies, 41 

of which are biotech companies; the rest provide support services. 

Berlin Adlershof is one of the most successful high-tech locations in Germany with 

focus on Photonics and Optics, materials and microsystems and media, biotechnology, 

and environment. There are currently 25 biotech companies in Adlershof occupying 

18,200 sq.m of lab and office space. 

berlinbiotechpark.de 

biotechcampus.de 

bio-luck.de 

cobiostechnologiezentrum.de 

bbb-berlin.de 

adlershof.de 

40



Other Parks 

GO:IN Golm 

Innovationszentrum GmbH 

Innovationspark Wuhlheide 

Science Park Potsdam-Golm is one of the most innovative and promising locations in 

Brandenburg. In the GO:IN facility, innovative companies will find an excellent working 

environment where they will benefit from the synergy effects of the location and the 

specific equipment offered by its laboratories. The location provides a wide range of 

services and consulting, as well as integration into the existing regional networks. 

So far 140 companies have decided to locate at the Wuhlheide Innovation Park, where 

the creative environment and service-oriented management provide important stimuli 

with respect to product development and innovation. Our companies have attractive 

office accommodation, workshops, laboratories and service areas at their disposal. 

Furthermore, they also have the opportunity to acquire fully developed investment sites 

for the evolution of their company! The location stands for successful new businesses, 

growth and long-term perspectives. 

wissenschaftsparkpotsdam.de 

goin-potsdam.de 

ipw-berlin.de 

IP Asset Management 

Ascenion 

ZukunftsAgentur Brandenburg 

GmbH Brainshell 

Ascenion advises public life science research institutions, universities, hospitals, freelance 

inventors and companies in all aspects of intellectual property asset management. 

Brainshell is an independent consulting agency specializing in intellectual property 

services for businesses.Brainshell manages and markets the patent portfolios of all 

colleges, universities, and research institutes in the State of Brandenburg. 

ascenion.de 

brainshell.de 

Universities and Research Centers 

BAM Federal Institute for Materials Research and Testing 

Berlin-Brandenburg Center for Regenerative Therapies (BCRT) 

BfR Federale Institute for Risk Assessment 

Brandenburg University of Technology 

Charité - Universitätsmedizin Berlin 

Deutsches Rheuma-Forschungszentrum Berlin 

Fraunhofer Institute for Applied Polymer Research (IAP) 

Fraunhofer Institute for Biomedical Engineering (IBMT) 

Freie Universität Berlin 

German Heart Instiute Berlin 

German Institute of Human Nutrition (DIfE) 

Humboldt-Universität zu Berlin 

htw Berlin – University of Applied Sciences 

Institute of Biomaterial Sciences, Helmholtz-Zentrum Geesthacht (Teltow) 

Institute for the Reproduction of Farm Animals Schönow Inc. 

Lausitz University of Applied Sciences 

Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB) 

Leibniz-Institut für innovative Mikroelektronik 

Leibniz-Institut für Molekulare Pharmakologie (FMP) 

Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch 

Max Planck Institute for Infection Biology 

Max Planck Institute for Colloids and Interfaces 

Max Planck Institute for Molecular Genetics 

Max Planck Institute of Molecular Plant Physiology 

Robert Koch Institute (RKI) 

Technische Universität Berlin (TU) 

University of Applied Sciences Berlin 

University of Applied Sciences Wildau 

University of Potsdam 

bam.de 

b-crt.de 

bfr.bund.de 

tu-cottbus.de 

charite.de 

drfz.de 

iap.fraunhofer.de 

ibmt.fraunhofer.de 

fu-berlin.de 

dhzb.de 

dife.de 

hu-berlin.de 

htw-berlin.de 

hzg.de 

ifn-schoenow.de 

fh-lausitz.de 

atb-potsdam.de 

ihp-microelectronics.com 

fmp-berlin.de 

mdc-berlin.de 

mpiib-berlin.mpg.de 

mpikg.mpg.de 

molgen.mpg.de 

mpimp-golm.mpg.de 

rki.de 

tu-berlin.de 

beuth-hochschule.de 

tfh-wildau.de 

uni-potsdam.de 

Banks and VCs 

BC Brandenburg Capital GmbH 

Berliner Sparkasse-Kompetenzzentrum Gründungen und Unternehmensnachfolge 

Berliner Volksbank eG 

bc-capital.de 

lbb.de 

berliner-volksbank.de 

41



Banks and VCs 

bmp Life Science AG 

Business Angels Club Berlin 

Commerzbank AG 

Creathor Venture 

Demeter Partners 

Deutsche Bank AG 

High-Tech Gründerfonds Management GmbH 

IBB Beteiligungsgesellschaft mbH 

Investitionsbank Berlin 

Investitionsbank des Landes Brandenburg 

KfW-Mittelstandsbank 

Peppermint Venture Partners GmbH 

Ventegis Capital AG 

XLHealth 

bmp.com 

bacb.de 

commerzbank.com 

creathor.de 

demeter-partners.com 

db.com 

high-tech-gruenderfonds.de 

ibb-bet.de 

ibb.de 

ilb.de 

kfw-mittelstandsbank.de 

peppermint-vp.de 

ventegis-capital.de 

xlhealth.de 

Supporting Organisations 

Berlin Partner für Wirtschaft und 

Technologie GmbH 

Support of international and domestic companies in all issues regarding locating 

to Berlin. 

berlin-partner.de 

Coaching Bonus Specific Coaching offers for innovative high tech companies. coachingbonus.de 

Investitionsbank Berlin (IBB) 

Investitionsbank des Landes 

Brandenburg 

Landesamt für Gesundheit und 

Soziales Berlin (LAGeSo) 

Technologie Stiftung 

Brandenburg 

Technologiestiftung Berlin 

ZAB Zukunftsagentur 

Brandenburg 

ZAK Zentrale Anlauf- und 

Koordinie rungsstelle 

Senatsverwaltung für Wirtschaft, 

Technologie und Forschung 

Company financing and consultation on subsidies and processing grant 

applications in Berlin. 

Company financing and consultation on subsidies and processing grant 

applications in Brandenburg. 

One Stop Agency for all licensing and approvals, for questions concerning biomedicine, 

biotechnology and pharmaceuticals and for more general issues connected 

with health, disease control and public health in Berlin. 

The technology Foundation Brandenburg is dedicated to the advancement of science 

and research, especially in the field of innovative technologies. 

The Technology Foundation Berlin is a public private partnership in the German 

capital region to develop science and industry networks for technology transfer, joint 

projects, and regional innovation strategies. 

The Brandenburg Economic Development Board functions as a one-stop agency for 

all kinds of business support services. 

Helps you find your way through the Berlin administration. Supports complex urban 

development policy and investment projects. 

ibb.de 

ilb.de 

berlin.lageso.de 

ts-bb.de 

tsb-berlin.de 

zab-brandenburg.de 

berlin.de/sen/wirtschaft/zak 

Pharmaceutical Companies 

Advance Pharma GmbH 

ALPHAMADE GmbH 

AstraZeneca 

Bausch & Lomb Dr. Mann 

Pharma 

Bayer Pharma Aktiengesellschaft 

Contract manufacturer of solid drugs.Galenic development and admissions, analytics 

and microbiology, coating and granulation (organic and aqueous), compacting, 

packaging. 

Customized formulations as medications: parenteral feeding, intradialytic parenteral 

feeding, omega-3 fatty acids, cytostatics. 

We are a global innovation-driven biopharmaceutical company specialising in the 

discovery, development, manufacturing and marketing of prescription medicines that 

make a meaningful difference in healthcare. We operate in over 100 countries and 

our medicines are used by millions of patients worldwide. AstraZeneca was formed 

on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC 

of the UK – two companies with similar science-based cultures and a shared vision 

of the pharmaceutical industry. 

Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing 

life for consumers around the world. Core businesses include soft and rigid 

gas permeable contact lenses and lens care products, and ophthalmic surgical and 

pharmaceutical products. 

Bayer Pharma is one of the ten largest specialty pharmaceutical companies in the 

world and the company's goal is a leading market position in each of its specialist 

fields. With its distinctive expertise in research, the company develops new medicines 

and therapies which make an essential contribution toward improving patient's 

quality of life. 

advance-pharma.eu 

alphamade.de 

astrazeneca.com 

bausch-lomb.de 

bayerhealthcare.com 

42




BERLIN-CHEMIE 

Aktiengesellschaft 

Chemisch-pharmazeutisches 

Labor, Rolf Sachse GmbH 

Daiichi Sankyo 

Dr. Kade Pharmazeutische Fabrik 

GmbH 

Haupt Pharma AG 

Heyl chemisch pharmazeutische 

Fabrik GmbH & Co. KG 

Klosterfrau Berlin GmbH 

medphano Arzneimittel GmbH 

MUCOS Pharma GmbH & Co.KG 

Pfizer Pharma GmbH 

Pharma Action GmbH 

PharmaMar GmbH 

Piramal Imaging GmbH 

Sanofi-Aventis Deutschland 

GmbH 

Shire Deutschland GmbH 

BERLIN-CHEMIE is a German subsidiary of the MENARINI Group. The company, 

which was formed in 1886 and is headquartered in Florence, was developed over 

the generations to become a global, owner-managed pharmaceutical company. Research 

is centred on the development of innovative drugs for the following areas: 

inflammatory diseases and pain, cardiovascular diseases, oncology, viral disease. 

CPL S: Custom synthesis development of active pharmaceutical ingredients (API’s), 

Contract manufacture of active pharmaceutical ingredients from laboratory to kiloscale, 

Pharmaceutical analysis. 

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. 

We provide innovative products and services in more than 50 countries around the 

world. With more than 100 years of scientific expertise, our company draws upon 

a rich legacy of innovation and a robust pipeline of promising new medicines to 

help patients. Through the outstanding knowledge and commitment of our 30,000 

employees worldwide, we create innovative new and generic medicines, and new 

methods of drug discovery and delivery. We share a passion for innovation, as well 

as compassion for the patients around the world who are in need of our medicines. 

The company’s activities concentrate on the production and marketing of drugs in 

the fields of gynecology, proctology, pain relief/ rheumatism and urology. The potential 

of proven drugs is expanded systematically by galenic developments to produce 

innovative products. 

With&nbsp,nine production sites Haupt Pharma is one of the leading contract manufacturers 

for pharmaceutical products in&nbsp,the world&nbsp,today.&nbsp,About 

2.000&nbsp,employees produce for an established clientele of more than 200 important 

international pharmaceutical companies, amongst which 15 of the international 

TOP 25. 

HEYL is an independent, entrepreneurial family business that has its headquarters in 

probably the liveliest German metropolis, Berlin, since its establishment in 1926. In 

cooperation with our international subsidiaries, the main focuses of our work are the 

Regulatory Affairs and marketing of medicines as well as the sale of active pharmaceutical 

ingredients (API's) and special chemicals. 

For more than 175 years Klosterfrau has been developing, manufacturing and marketing 

pharmaceutical products. The profile of traditional yet modern natural medicines 

has grown significantly in recent times. Based on the latest scientific discoveries 

combined with the development of new markets, the range is constantly being 

expanded with innovative products. 

medphano Arzneimittel in Rüdersdorf stands for proven and cost-effective pharmaceutical 

preparations. Main products are analgesics/anti-rheumatics, antibiotics, 

dermatics, diuretics, drugs to stimulate blood circulation, drugs for treatment of gastro-intestinal 

disorders, vitamins, expectorants, lipid-lowering agents, ophthalmics, 

cosmetics, food supplements, diet foods and foods. 

As a specialist in enzyme preparations Mucos supplies a steadily growing market 

with specific and variably dosed enzyme combinations. The company leads the 

world market in oral enzymes for therapeutic purposes. 

Pfizer is the world's largest research-based biomedical and pharmaceutical company. 

Pharma Action has extensive expertise in global pharmaceutical marketing and manufacturing 

since 1988 and offers cutting edge API solutions to the pharmaceutical 

industry in Europe and abroad. 

PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in 

discovering, developing and marketing marine-based drugs to treat cancer. Yondelis 

® is the first marine-based antitumour drug. PharmaMar has four other compounds 

in clinical development: Aplidin ® , Zalypsis ® , PM01183 and PM060184. PharmaMar 

also has a rich pipeline of pre-clinical candidates and a major R&D programme. 

PharmaMar GmbH, the German subsidiary, was officially established in November 

2013 in Berlin. 

Piramal Imaging is a start-up business within the Life-Science division of the Mumbai-based 

Piramal Enterprises Group. The company is dedicated to the clinical research 

& development and the global commercialization of Nuclear Medicine / Molecular 

Imaging products for detection, characterization and monitoring of disabling 

and life-threatening diseases in neurology, oncology and the cardio-vascular space. 

Sanofi-aventis is a leading global pharmaceutical company based in Paris and operating 

in over 100 countries. R&amp,D teams work on a global approach to patients, 

offering innovative therapeutic strategies in thrombosis, cardiovascular diseases, 

diabetes, vaccines, oncology, the central nervous system disorders and internal 

medicine. 

Shire’s strategic goal is to become the leading specialty biopharmaceutical company 

that focuses on meeting the needs of the specialist physician. Shire focuses its 

business on attention deficit and hyperactivity disorder, human genetic therapies and 

gastrointestinal diseases. 

berlin-chemie.de 

cpl-sachse.de 

daiichisankyo.com 

kade.de 

haupt-pharma.de 

heyl-berlin.com 

klosterfrau.de 

medphano.de 

mucos.de 

pfizer.de 

pharma-action.com 

pharmamar.com 

imaging.piramalenterprises. 

com 

sanofi-aventis.de 

shire.de 

43




Spreewälder Arzneimittel GmbH 

Steiner & Co. Deutsche 

Arzneimittelgesellschaft mbH & 

Co. KG 

Steripharm Pharmazeutische 

Produkte GmbH & Co. KG 

Takeda GmbH 

Teva GmbH 

Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food 

supplements, diet foods and cosmetics in liquid, semi-solid and solid administration 

forms. 

Production and marketing of pharmacy and prescription drugs, particularly plantbased 

drugs (tranquillizers, rheumatism drugs, bile duct and gastro-intestinal as well 

as gynecological and urological drugs), analgesics and mineral preparations. 

Production and marketing of folic acid products. 

Takeda is Japan´s and Asia´s largest pharmaceutical company and among the leading 

global companies of its branch, represented in more than 70 countries. Takeda 

committed itself for a better health care of patients all over the world by innovations 

in medicine. Its therapeutical core areas are metabolic, cardiovascular, inflammatory, 

immune and respiratory diseases, diseases of the central nervous system, oncology, 

gastroenterology and pain. 

Teva in Germany is the leader in generics and an expert in innovative brand business. 

The German headquarter is located in Ulm. Patent-protected medicines from 

the fields of neurology, oncology, pain management and respiratory diseases are 

marketed by Teva Specialty Medicines in Berlin. Teva Specialty Medicines’ primary 

area of success is neurology. The first product to be come from the company's own 

development facility contains the active ingredient glatirameracetate and is the market 

leader among drugs used to treat multiple sclerosis. Another product from Teva’s 

own research laboratories, is a standard in the treatment of Parkinson’s disease. 

spreewaelder-arzneimittel.de 

steinerarznei-berlin.de 

steripharm.de 

takeda.de 

teva.de 

Contract Manufacturers 

Advance Pharma GmbH 

ALPHAMADE GmbH 

Ayanda GmbH & Co. KG 

Chemisch-pharmazeutisches 

Labor, Rolf Sachse GmbH 

Haupt Pharma AG 

Pharma Action GmbH 

Spreewälder Arzneimittel GmbH 

Contract manufacturer of solid drugs.Galenic development and admissions, analytics 

and microbiology, coating and granulation (organic and aqueous), compacting, packaging. 

Customized formulations as medications: parenteral feeding, intradialytic parenteral 

feeding, omega-3 fatty acids, cytostatics. 

Ayanda is an innovative business partner and manufacturer of consumer ready pharmaceuticals 

and food supplements. In Pritzwalk, Brandenburg, the company has a 

pharmaceutical soft gel encapsulation plant. 

CPL SACHSE offers: Custom synthesis development of active pharmaceutical ingredients 

(API’s); Contract manufacture of active pharmaceutical ingredients from laboratory 

to kiloscale; Pharmaceutical analysis. 

With nine production sites Haupt Pharma is one of the leading contract manufacturers 

for pharmaceutical products in the world today. About 2.000 employees produce for an 

established clientele of more than 200 important international pharmaceutical companies, 

amongst which 15 of the international TOP 25. 

Pharma Action has extensive expertise in global pharmaceutical marketing and manufacturing 

since 1988 and offers cutting edge API solutions to the pharmaceutical industry 

in Europe and abroad. 

Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food 

supplements, diet foods and cosmetics in liquid, semi-solid and solid administration 

forms. 

advance-pharma-berlin.de 

alphamade.de 

ayanda.com 

cpl-sachse.de 

haupt-pharma.de 

Pharma-action.com 

spreewaelder-arzneimittel. 

de 

Contract Research Organisations 

analyze & realize ag 

Allied Clinical Management 

GmbH 

Assign International GmbH 

BLS Preclinical Services 

analyze & realize ag is a leading CRO and consulting firm, which primarily give complete 

advice and guidance to companies in the natural products sector. 

The CRO has broad experience in monitoring and managing phase I to phase IV clinical 

trials including advanced therapy medicinal product (ATMP) trials as well as in 

accompanying and conducting medical device trials and post-marketing surveillance. 

Assign International in Berlin is part of the Assign Group, a mid-sized full-service CRO 

with six offices in five countries.Our expertise meets development requirements of 

pharmaceutical and biotechnological industries. We manage clinical trials from study 

set-up to final clinical report.Our services, among others, comprise Data Management 

and Biostatistics, integrated EDC-Systems, Pharmacovigilance, Protocol Writing, Laboratory 

Services and Quality Management. 

BLS Preclinical Services is a contract research organization (CRO) located in Berlin. 

BLS provides a range of highquality and integrated preclinical services in animal models. 

Through our highly skilled scientific partners we provide a “one-stop” service and 

tailored solution. We take the time to understand your business needs and provide comprehensive 

tailored solutions either in-house or in co-operation of our network. We are 

backed by a highly skilled scientific team with a wealth of experience in all disciplines 

of preclinical development. 

analyze-realize.com 

allied-clinical.com 

assigngroup.com 

bls-germany.com 

44



Contract Research Organisations 

CBR Biotech Strategies GmbH 

Charité Research Organisation 

GmbH 

Cooperative Clinical Drug 

Research and Development 

(CCDRD) AG 

CSG Clinische Studien 

Gesellschaft mbH 

Dr. Notghi Contract Research 

Klinische Forschung Berlin GbR 

Klinische Forschung Gruppe 

Nord GmbH 

Lampe & Company 

GmbH & Co. KG 

MEDIS RESEARCH GROUP 

OSMUNDA Medical Device 

Service Group 

PAREXEL International GmbH 

PharmaLex GmbH 

Sacura GmbH 

WITEGA Laboratorien Berlin- 

Adlershof GmbH 

CBR International Corporation is a global, full-service product, clinical, and regulatory 

compliance development group dedicated to providing comprehensive consulting services. 

We understand commercial pressures and regulatory constraints of biopharmaceutical 

product development and offer full support and guidance to all of our clients. 

Our experienced staff and consulting affiliates offer detailed and strategic services 

to members of the biotechnology, pharmaceutical, and device industries worldwide. 

Based in Berlin, the Charité Research Organisation (CRO) was founded in collaboration 

with Berlin‘s famous Charité University Hospital. This relationship fosters a level of cooperation 

with centers of clinical excellence that we think is unique in the industry. The 

CRO offers a whole new approach to the concept of partnering with centers of clinical 

excellence to facilitate access to patients, clinical expertise and specialist methodologies 

in support of early clinical development programs. 

CCDRD is an independent contract research organization (CRO). CCRDR is dedicated 

to offer creative and innoative full service from planning to market authorization to its 

customers in the pharmaceutical, biotechnological and medical device industry. 

Since its foundation in 1998, the CSG Clinische Studien Gesellschaft mbH has focussed 

on aligning clinical research with public health demands, with special attention to facilitating 

access by physicians and patients to clinical studies.CSG cooperates closely 

with the largest research institute for public health in Germany, the IGES Institut. 

Dr. Notghi Contract Research GmbH is a service provider for large, medium and smallsized 

companies in the pharmaceutical, generics and biotechnology industries. We 

support and advise you in the conduct and management of national and international 

projects. 

Klinische Forschung Berlin is a study centre that implements clinical studies from 

phases IIA to IV for the pharmaceuticals industry. 

The Klinische Forschung Gruppe Nord (Clinical Research Group North) is a network 

of independent investigator institutes with five centres in Northern Germany, two of 

them in Berlin.The Klinische Forschung Gruppe Nord has carried out trials with up to 

250 patients. Phase II and III studies are the core competence. The test centres have 

altogether 30 overnight accommodation places for phase I and IIa studies. 

Lampe & Company is a consulting firm specialized in multidimensional analysis of 

biomedical literature for evidence-based decision making. Our team of experts combines 

industry expertise with our unique L-Matrix Method and exclusive L&C relational 

database to deliver critical information to leading decision makers of pharmaceutical, 

life sciences, and medtech companies. 

MEDIS RESEARCH GROUP is a partnership of clinical research services providers with 

a joint mission to combine clinical research expertise and provide complete service 

solutions across all stages of the clinical development process. 

OSMUNDA is the largest Chinese clinical trial CRO and service provider for the medical 

device and in-vitro diagnostic industry. Over 2000 international clients have entrusted 

our expertise in regulatory affairs, clinical trials and industrial distributor/supplier resources 

to achieve their business goals. 

The German subsidiary of the US clinical research organization PAREXEL employs 

more than 1,400 people in Berlin. In two units with a 160-bed capacity (incl. 8 sleep lab 

beds) and an annual enrollment of approximately 2,500 volunteers in Berlin, more than 

75 clinical studies are performed each year. 

PharmaLex is one of the leading service providers in the International pharmaceutical 

business. The company is dedicated to the development, registration and marketing 

authorization, market access and product maintenance of medicinal / biotechnological 

products and medical devices, worldwide. The corner stones of PharmaLex’ successful 

co-operation with companies of all sizes and specializations are very high quality of 

work, reliability, efficacy, flexibility and anticipatory strategic planning. 

Sacura is a full-service contract research organization granting a high level of quality 

(FDA approved), flexible structures and qualified staff. 

WITEGA Laboratorien Berlin-Adlershof GmbH is a medium-sized company specializing 

in the realization of organic customer syntheses. Our customers are companies from 

the chemical and pharmaceutical industries as well as from other technology fields. The 

main focus of our activities is the lab-scale custom synthesis of organic building blocks, 

intermediates and target structures and of isotope-labeled compounds (D, 13C, 15N) 

for chemical and pharmaceutical research and development. The company is also a 

supplier of analytical standards for residue analysis (especially in veterinary medicine). 

cbrintl.com 

charite-research.org 

ccdrdag.com 

csg-germany.com 

notghi.com 

klinische-forschung-berlin. 

de 

kfgn.de 

lampeandcompany.com 

medis-research.com 

osmundagroup.com 

parexel.com 

pharmalex.com 

sacura-cro.com 

auftragssynthese.com 

45



Biotech Companies 

3B Pharmaceuticals GmbH 

8sens.biognostic GmbH 

ABiTEP GmbH 

Accelero Bioanalytics GmbH 

Acuros GMBH 

3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company 

based in Berlin, Germany. The company is dedicated to the development of peptide-based 

pharmaceutical and diagnostic products. 3BP is pursuing projects in hemophilia 

and nuclear medicine. 

8sens.biognostic develops, produces and sells rapid tests (lateral-flow) and ELISAs for 

different markets (human and veterinary diagnostics, food control). Our products are 

the QuickSens ® -tests for h-FABP, TropI, CRP and hs-CRP and the Reader for quantification 

QuickSens ® OMEGA. Development-on-demand, feasibility studies and production-on-demand 

are also offered. 

The ABiTEP GmbH is working in development and production of biotechnological products 

for sustainable agriculture. The team of ABiTEP works for development of non 

GMO customer specific technologies in laboratory scale and scale up with modern 

equipment and Know how. Capacities for fermentation up to 5.000 L, down stream 

equipment as well as freeze drier with capacity of 90 L are available for services. A 

molecular biology lab is available for basic science. 

Accelero ® Bioanalytics GmbH is a biotech CRO focussing on GxP compliant bioanalytical 

ligand binding assays. The company supports PK and PD preclinical/ clinical drug 

development on microRNA, miRNA, siRNA, aptamers, plasmid APIs, antisense drugs, 

as well as peptide hormones, biosimilars, antibody therapeutics, or cell-based therapeutics 

(ATMP). The Applied Biosystems Viia7 real-time qPCR system with IVD label for 

human Dx operates in full compliance to Good Laboratory Practice (GLP). 

Development of osmotic micropumps for medical or microfluidic applications.The innovative 

technology enables new options in liquid handling – from disposable micropumps 

for drug delivery to precision micropumps for lab-on-a-chip development. 

3b-pharma.com 

biognostic.de 

abitep.de 

accelero-bioanalytics.com 

acuros.de 

Adrenomed AG Development of biologics against severe sepsis. adrenomed.com 

Aevotis GmbH 

AFOSA GmbH 

Aglycon Mycoton GmbH 

AJ Innuscreen GmbH 


Alcat Europe GmbH 

Algenol Biofuels Germany GmbH 

ALRISE Biosystems GmbH 

Amal Therapeutics S.A. 

Amocol Bioprocedures Ltd. 

AnaKat Institut für 

Biotechnologie GmbH 

The core competencies of aevotis lie in the targeted conversion of simple carbohydrate 

containing substrates (e.g. agricultural by-products, waste streams, inexpensive 

sugars) to high-value carbohydrate based products, their characterization, processing 

and testing. Marketable products include novel /optimized enzymes, expression systems,&nbsp, 

specialized biotransformation and down-stream processes, customized 

oligomers and polymers for food and non-food uses. 

Development, production and marketing of diagnostics (ELISA kits), primarily for use 

in veterinary medicine. 

Aglycon Mycoton GmbH is active in the research, development and application of biopolymers 

as well and their manufacture and the sales and marketing of products based 

on these. 

The AJ Innuscreen GmbH is a young life science company working in the field of biotechnology 

and boosts the life science unit of Analytik Jena AG. Innovative technologies 

and products are developed and produced for the isolation and purification of nucleic 

acids. Reagent systems for molecular biology, as well as technologies and products 

for molecular diagnostics, are also included in the product portfolio. The company is 

EN ISO 9001:2008 and EN ISO 13485:2003 + AC:2009 certified. 

Alacris Theranostics GmbH is a company based in Berlin specialised in developing 

new approaches in personalised medicine for cancer patient diagnosis, treatment and 

drug stratification. Alacris is applying a systems biology approach that has been developed 

in the Department of Prof. Lehrach at the Max Planck Institute for molecular 

Genetics and is exclusively licensed as ModCellTM to Alacris. 

Alcat Europe GmbH is the daughter of the US company Cell Science Systems, the original 

developer of the Alcat test technology. The company is specialized to identify intolerant 

reactions of the leucocytes to foreign substances like foods, drugs or chemicals. 

The company focuses on the biotechnological use of cyanobacteria, especially the 

development and optimization of cyanobacteria for the production of environmentally 

friendly biofuels and chemical feedstocks. 

ALRISE is a drug delivery company that specializes in the nano- and micro-encapsulation 

of active ingredients. Using its globally patented ImSus ® technology, ALRISE are 

developing parenteral deposit pharmaceutical forms for proteins, peptides or small 

molecules. Customers are mainly large pharmaceutical companies who are developing 

improved administration forms for active ingredients whose patents are expiring together 

with ALRISE as part of their “Product Lifecycle Management”. 

Amal Therapeutics SA is a Swiss biotech start-up company and spin-off from the University 

of Geneva with a subsidy in Berlin. Amal uses its proprietary cell penetrating 

peptide platform to develop and progress therapeutic vaccines in oncology. 

Amocol Bioprocedures Ltd is a life science research & development and manufacturing 

company headquartered in Germany. Our mission is to supply innovative affinity chromatography 

media products and protein purification tools for research scientists and 

clinical customers in public sector institutes and industry. 

AnaKat Institut für Biotechnologie GmbH has specialized on analytical determination of 

pharmaceutical ingredients. 

aevotis.com 

afosa.com 

aglycon-mycoton.net 

aj-innuscreen.de 

alacris.de 

alcat-europe.com 

algenol.com 

alrise.de 

amaltherapeutics.com 

amocol.com 

anakat.de 

46




Analyticon Discovery GmbH 

Analytisches Zentrum Biopharm 

Berlin GmbH 

AnaTox GmbH & Co. KG 

Anau Berlin-lab GmbH 

ANiMOX GmbH 

Aokin AG 

ARGUS Umweltbiotechnologie 

GmbH 

Artemiflow GmbH 

ASCA GmbH Angewandte 

Synthesechemie Adlershof 

Astra Biotech GmbH 

ATLAS Biolabs GmbH 

Attomol GmbH Molekulare 

Diagnostika 

AudioCure Pharma GmbH 

AutoTissue GmbH 

Avitop GmbH 

AnalytiCon is a biotechnology company focusing on the development of compound 

libraries consisting of natural product (NP) and synthetic small molecules. As the global 

market leader in NP small molecule screening compounds, AnalytiCon is the only 

company which is able to provide vast collections with completely disclosed structural 

information. As a pure compound provider the company is offering its products and 

services to the pharmac., chemical, biotech, cosmetical and nutraceutical industry. 

Analytisches Zentrum Biopharm GmbH Berlin is a contract research organization providing 

services on pharmaceutical analysis and bioanalysis for active compounds in 

the dosage form, for the quantitative determination of analytes in a biological matrix 

and also the determination of physicochemical parameters of chemicals according 

to OECD guidelines. AZB carries out these services in compliance with GLP and GMP 

and has the GLP certificate. 

The AnaTox GmbH & Co. KG deals with the development and optimization of analytical 

methods and devices for HPLC and dissolution. 

Development and distribution of lab devices. 

Development of applications for the use of natural peptide / amino acid mixtures in 

chemistry and biotechnology, f.i. as a scavenger material in formaldehyde bounded 

formulations, foaming or hydrophobic Tensid compounds or as a N-source in biotechnological 

fermentation processes, distribution of a technology for the production of 

such basic materials from raw and residual materials. 

Aokin AG is a Berlin biotechnology company that is specialized in the development 

and commercialization of innovative analytical systems on the base of the rapid kinetic 

assay technology. The aokin systems are unique in their precision and operating speed. 

Areas of application are food and antibody analytics as well as clinical diagnostics. 

We also offer laboratory services in the area of food analytics, Pharmacoanalytics and 

chemical synthesis. 

ARGUS is a medium-sized company. Since 1987 ARGUS works on the field of remediation 

of contaminated groundwater, soil, waste water and waste air. ARGUS is able to 

elaborate a specific remediation program in each different pollution case considering 

economic aspects beside ecological aspects. All necessary treatment steps can be 

planned and carried out. The combination of microbiological steps with classic processes 

leads to a successful remediation of complex contamination. 

Artemiflow is a spin-off from the Max Planck Institute of Colloids and Interfaces (MPIKG). 

By the industrial use of an international patent held by MPIKG, Artemiflow uses a new 

process to produce Artemisinin from dihydroartemisinic acid (DHAA). DHAA is available 

in abundance in the waste of the current production process for Artemisinin. 

ASCA is a partner for contract research in the field of medicinal chemistry. The synthesis 

and optimization of lead structures, the development of new active structures 

and their check on a laboratory scale are offered. We take a lot of care on working out 

the synthetic schemes, rapid preparations and exact analysis of the samples. All our 

results are carefully documented for our customers. Access to literature databases and 

in-house analytical facilities are available. 

Astra Biotech GmbH offers high quality reagents, allergens, antibodies, recombinant 

proteins, and assays for the determination of hormones, allergies, tumour markers and 

infectious diseases. Quality is one of the key cornerstones on which Astra Biotech maintains 

its reputation and with which we strive to increase customer satisfaction and gain 

growing customer loyalty. We take great pride in our highest quality assays, which are all 

IVD compliant and therefore suitable for direct, accurate and reproducible diagnostic 

purposes, as well as for research. 

ATLAS Biolabs GmbH is a leading provider of microarray based genomic services 

such as genome wide gene expression and SNP analysis, CGH analysis and diagnostic 

services for registered doctors and hospitals, as well as for pharmaceutical, biotechnological 

and diagnostic enterprises. 

The company’s aim is to develop, produce and distribute medical diagnostics for human 

medicine in the field of molecular genetics, infectious and autoimmune diseases. 

AudioCure is focus on the clinical development of drug candidates for neurodegenerative 

diseases with high unmet medical need. 

The company is engaged in the development, production and marketing of medical devices 

for cardiovascular surgeons. The products are specially made for the patients and 

have less side effects. The first certified product was a pulmonary heart valve (Matrix P) 

for the right ventricular outflow tract reconstruction (RVOT). The second product is also 

a heart valve which considerably shortens the operation time (Matrix P plus). Meanwhile 

a complete glutaraldehyde free valve is available called Matrix P plus N. 

Avitop is focusing on probiotics and food concepts with specific health indications. 

Based on the highest scientific standards, we develop a new generation of probiotics 

and food with unmet specific functions.We deliver the food industry with new and specific 

solutions for actual and future health challenges facing modern society. 

ac-discovery.com 

analytisches-zentrumbiopharm.de 

anatox.de 

animox.de 

aokin.com 

argus-umwelt.de 

artemiflow.com 

asca-berlin.de 

astrabiotech.de 

atlas-biolabs.com 

attomol.de 

audiocure.de 

autotissue.de 

avitop.de 

47




Bbi-biotech GmbH 

BEB BioEnergy Berlin GmbH 

BG Berlin-Genetics GmbH 

Bioanalyt GmbH 

Bioassays GmbH 

Biochrom AG 

BIOCYC Gesellschaft für 

Biotechnologie und Recycling 

mbH & Co.KG 

BioGenes GmbH 

Bioline GmbH 

BioMedion GmbH 

Biopract GmbH 

Biorefinery.de GmbH 

BioRepro GmbH 

BioS Biotechnologie Schönow 

GmbH 

BioSilta Europe GmbH 

BIOSYNTAN Gesellschaft für 

bioorganische Synthese mbH 

In the focus of the activities of bbi-biotech lie systems for the sterile sampling from 

bioreactors for all applications in the biotechnology, pharmaceutical, food, cosmetics 

and chemical industry. In addition, bbi-biotech develops components - in especially 

disposable ones - for the preparation of a new generation of fermentors and bioreactors 

and offers consulting and planning services for biotech projects, its implementation 

and services. 

Planning, Design, Construction, Supervision and Implementation of Biogas/Hydropower 

plants, Preplanning, Feasibility Studies and Research activities in the field of renewable 

energies, Optimization of the process in existing biogas plants. 

BG Berlin-Genetics GmbH is a new provider for genetic diagnostics and consulting in 

genetic diagnostics. We are a team of experienced human geneticists and have worked 

for many years in the field of human genetic science and human genetic diagnostics. 

Our aim is the development of innovative cooperation concepts, to connect classical 

patient-based medical care centers with modern technology-based service centers. 

In future, these cooperation forms will enable efficient, high quality, and patient-based 

genetic diagnostics. 

Bioanalyt develops and distributes the worldwide first easy-to-use and portable test kits 

for the analysis of vitamins and micro nutrients. The iCheck-iEx test kits enable food producers, 

food authorities and NGOs to monitor their ongling food programms more efficiently 

and at low-cost. The company was founded in 2006 by Prof. Dr. F. J. Schweigert 

as a spin-off of the University of Potsdam. Read more on our website bioanalyt.com. 

Service related to the development of medical in vitro-diagnostic products. Basic science 

to clinical development. Profiling of biomarkers in clinical trials. 

Biochrom is Germany’s largest manufacturer of cell culture products (media, sera, and 

others) and sterile liquids. They are distributed to universities, industrial cell culture 

laboratories and industrial manufacturers. Service is of special significance for users 

of cell cultures. Special media developments and production optimizations are offered. 

Production of bio-chemicals, peptides, in vitro-diagnostics, test-kits. Development of 

consumer service for peptides and biochemicals. 

BioGenes is a full service immunoassay and antibody (monoclonal and polyclonal) 

development company with outstanding problem solving capabilities specializing in 

challenging projects that are carried out by an exceptionally experienced and interdisciplinary 

team. 

Our mission is to provide customers with a range of products which are fast and easy 

to use, guaranteed to work and developed by scientists who understand what our customers 

are trying to achieve so they can focus on their scientific goals. Bioline reagents 

are used by molecular biologists and other research scientists to perform test-assays 

and research in many fields from medical, biotechnology and marine biology. 

IT-Service for all GxP-Regulatory Tasks Data- and Document Management, Long-Term- 

Archiving and Digital Signature, SOP-Management, CAPA, Raw Data Management, 

Consulting for Validation of Computerized Systems according to GAMP4/5. 

Service and Additives (enzymes, trace elements, microbes) for biogas and waste water 

sludge treatmentEnzyme analysis in agriculture industry Contract reserach feed 

additives. 

Based on main precursors of plants, carbohydrates in kind of sugar, starch and cellulose, 

and proteins, the biorefinery.de company has developed four complex product 

lines (Biorefinery systems) which leads to a great number of valuable products with the 

help of chemistry and biotechnology. 

BioRepro is the first pharmac. company, whose core competency is the breeding of 

leeches under controlled laboratory conditions for medical therapies. We concentrate 

on the establishment of GMP breeding procedures and will be able to provide leeches 

with standardized quality while equally allowing scalability to supply medical demand. 

Additionally, through the re-initiation of fundamental research, we will gain deeper understanding 

of further potential in medical and cosmetic treatment areas. 

Embryo transfer and associated biotechnologies in animals. Service, training and research 

in this field. 

BioSilta is an international company that specializes in advanced tools for microbial 

cell cultivation, protein production, enzyme screening and food spoilage testing. The 

patented EnBase ® technology resembles fed-batch mode and provides a cultivation 

environment with glucose-control, pH maintenance and inhibition of growth-limiting 

metabolites without the need for traditional mechanical pumps. EnBase ® is provided in 

ready-to-use liquid or tablet products. BioSilta specializes in small-scale cultures and 

it?s products offer customer solutions from multi-well plates to small-scale bioreactors. 

Learn more about our products and applications at biosilta.com. 

BIOSYNTAN offers the custom synthesis of standard peptides, the synthesis of modified 

peptides (e.g. glyco- and phosphopeptides, dye labeled peptides) and hapten 

modifications for the conjugate synthesis. In cooperation with BIOGENES GmbH Berlin 

we offer poly- and monoclonal antibodies. 

bbi-biotech.com 

bebgmbh.de 

bg-berlin-genetics.de 

bioanalyt.com 

bioassay-online.de 

biochrom.de 

quartett.com 

biogenes.de 

bioline.com 

biomedion.com 

dsmbiogas.com 

biorefinery.de 

biorepro.de 

bios-schoenow.de 

biosilta.com 

biosyntan.de 

48




Biotech-Laboratorium für 

Environment BLE GmbH 

biotechrabbit GmbH 

BIOTECON Diagnostics GmbH 

BioTeZ Berlin-Buch GmbH 

BIOWORX -Biotechnologielabor- 

Thomas Grimm 

BiRDS Pharma GmbH 

Blue Biolabs GmbH 

Botiss medical AG 

BST Bio Sensor Technology 

GmbH 

Caprotec bioanalytics GmbH 

Capsulution Pharma AG 

Celares GmbH 

Cell Medica GmbH 

Development of detection systems which are able, economically and rapidaly, to detect 

oil contaminations and industrial oil waste, in soil and in water and their biological depletion. 

The BLE GmbH is concerned with the biological degradation of oil contaminations 

and the development of a set of bio-preparations consisting of different bacterial 

strains which break down oil. 

biotechrabbit GmbH is determined to offer the newest and best life science products 

and innovative solutions to scientists leading the fight againstdisease and fueling our 

lives with innovations. We supply ultra pure enzymes and high-quality antibody services 

for diagnostics and a life science product portfolio(including reagents for PCR 

and nucleic acid purification)for molecular biology and proteomics. The biotechrabbit 

advantage is our combination ofpassion for excellent research with the agility of true 

entrepreneurship. 

BIOTECON Diagnostics has been well known as a qualified partner in the field of molecular 

and microbiology for the last 13 years. We focus on development, production 

and marketing of PCR-based rapid detection systems. BIOTECON Diagnostics offers 

solutions for the food and beverage industry as well as for producers of pharmaceuticals 

and cosmetics. 

Services (Custom DNA and RNA Oligonucleotide synthesis, Immuno affinity columns) 

- Development of Enzyme Immunoassays, e.g. for Therapeutic Antibodies- Bio Conjugates 

- Immobilization of Bio Molekules for better Signalling-R&D (Aptamer). 

BIOWORX offers services in the fields of contract research for customer-specific Biotransformations, 

the screening, isolation and production of Biocatalysts from microorganisms 

and plants and the bioanalytic syntheses. Further organic compounds and 

metabolites will be synthesized with enzymes for customer in kg scale. 

BiRDS Pharma GmbH, integrated into the BDD/CCDRD group, provides services in the 

field of drug development to pharmaceutical and biotech companies, including management 

of drug development projects as well as consulting services. The company 

also pursues own drug development projects based on intellectual property generated 

within BDD/CCDRD group, with a focus on drug candidates derived from Atomic Substitution 

Technology (AST). 

Blue Biolabs is a spin-off company from the TU-Berlin, which specialises in the development 

of products and services in the field of environmental analysis using methods 

of microbiology and molecular biology. 

Botiss biomaterials is a privately owned biotech company, headquartered in Berlin. 

botiss is the leading German specialist for dental bone and tissue regeneration (BTR). 

We focus on the development of innovative regenerative materials and clinical marketing 

/ distribution in over 50 countries world-wide. The botiss subsidiary Cell+Tissue 

Bank Austria is a leading European manufacturer of allogenic materials for hard tissue 

regeneration. 

BST develops and produces biosensors to provide high quality analysis at moderate 

prices. In 1982 BST brought on the market the first multi-way biosensor based blood 

glucose analyzer in Europe and is since then market leader in Europe. Today BST sells 

more than 60.000 sensors a year. Since 2008 BST is besides biosensors also manufacturer 

of POCT and laboratory instruments. 

Caprotecs Capture Compound Mass Spectrometry (CCMS) Technology allows separation 

and isolation of proteins based on functionality. For many applications, CCMS is 

clearly superior to conventional methods - thus addressing an unmet need in the proteomics 

research community. The company is commercializing the CCMS technology 

through ImproMed projects with pharmaceutical and biotechnology companies. The 

focus on these collaborations is on investigating mechanisms of drug action (MoA) 

and identification of on- and off-target proteins to understand potential adverse effects 

of drug candidates on a molecular level. This can be easily carried out in the lead 

optimization process, or even earlier to increase the probability of success later on in 

the clinic. 

Capsulution Pharma AG develops innovative nano- and micron-sized capsules. The 

company applies its worldwide-patented so-called LBL-Technology ® . Based on their 

minute size, their functionality and their highly reproducible production process the 

capsules can be used for a multitude of different applications. Accordingly, the precisely 

sized capsules (500 nm to 50 µm) can be made to function in a manner to suit the 

intended application, and can be given the appropriate biochemical, electrical, optical 

and magnetic properties as required by the customer. 

Specialist for Drug Delivery of peptides/proteins by using PEGylation. Modification of 

Biopharmaceuticals with polyethylene glycol in order to substantially improve pharmacological 

properties. Offers the unique CelaSYS-PEGylation technology, which is 

patented by celares. CelaSYS: non-dispersed, highly branched polyethylene glycol 

based reagents. Additionally celares offers customized PEGylation solutions as well as 

synthesis of customized PEG-reagents. 

Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics 

for infectious disease and cancer. 

mobiclup.de 

biotechrabbit.com 

bc-diagnostics.com 

biotez.de 

bioworx.de 

birdspharma.com 

bluebiolabs.de 

botiss.com 

bst-biosensor.de 

caprotec.com 

capsulution.com 

celares.com 

cellmedica.co.uk 

49




CellServe GmbH 

CellTrend GmbH 

Chemicell GmbH 

Chipron GmbH 

CHIRACON GmbH 

CMZ-Assay GmbH 

co.don ® AG 

CONGEN Biotechnologie GmbH 

Cyano Biotech GmbH 

DendroPharm GmbH 

DexLeChem GmbH 

Diaglobal GmbH 

DIZG Deutsches Institut 

für Zell- und Gewebeersatz 

gemeinnützige GmbH 

Dr. Götz Verfahrenstechnik 

Biotechnik Umwelttechnik 

Dr. Lerche KG 

Dr. Otto GmbH 

Dr. Rölleke Labor für Genetische 

Analytik GmbH 

CellServe is a service provider for research groups in regenerative medicine and fills an 

important gap in the conversion of applied treatment concepts from research into marketable 

products. Furthermore CellServe develops own innovative cell-based products 

for cardiology and uses novel cardiac derived cells ("From the Heart to the Heart") for 

the treatment of chronic heart failure. 

Celltrend is certified according to ISO 9001, ISO 13485 and GMP Cell culture systems 

for research on active substances (bioassays, preclinical research, for quality control) 

Development and production of antibody-based detection systems (ELISA) Chemosensitivityassay 

for optimisation of chemotherapy (tumor patients). 

Chemicell develops and produces magnetic, fluorescent and coloured nano- and microparticles, 

reactive fluorescent dyes and special chromatography-materials for the 

separation or detection of cells, bacteria, viruses, proteins or DNA/RNA and new gene 

transfer systems. 

Chipron GmbH specializes in production and distribution of array based detection systems 

for DNA/pathogens. 

chiracon is a qualified partner to develop chiral intermediates at a constant high quality 

for innovative drugs regarding economic, environmentally acceptable and scaleable 

aspects. We offer support through expert knowledge and key technology to meet your 

increasing needs. Our core competence is chirality. In addition we have a broad variety 

of chiral building blocks as an inhouse raw material source for high-level API production 

and development. 

Marketing of diagnostic reagents for measuring concentrations of proteins, hormones 

and their isoforms, exclusively for research purposes. 

co.don ® AG is one of the leading biopharmaceutical companies in the area of RegenerativeMedicine/Tissue 

Engineering. Since 1997, co.don ® AG has developed, manufactured 

anddistributed human Tissue engineering therapeutics for the regeneration of 

articular cartilage and intervertebral discs. 

CONGEN is specialized in food testing by molecular analytics based on DNA and RNA 

detection. CONGEN has been a pioneer for over a decade in the development and 

application of food and feed analytics by real-time PCR. The methods are available 

as complete analytic kit as well as a Service. Our mission is to serve the food industry 

with an excellent service and with standardized and reliable test kits in order to realize 

highest possible food safety and food quality. 

Cyano Biotech identifies and characterizes natural products from cyanobacteria and 

optimizes their pharmacological activities employing a biocombinatorial approach. The 

company conduct further development of identified lead structures till the preclinical 

phase. 

DendroPharm, a spin-off from the Free University of Berlin, develops innovative customized 

to drugs nanocarriers, which allow active pharmaceutical ingredients more 

focused and objective to bring: in tumor tissue, cartilage or into the skin. 

We are experts in the reactivation of complex chiral catalysts. For the first time the 

unmodified homogeneous catalyst can be re-used repeatedly thanks to our innovative 

water based process. Supported by quantum chemical analysis we are able to simulate 

catalytic cycles. Combined with our special knowhow this enables us to find the best 

solvent system for our customers. By using this new resource-efficient reaction route our 

customers – manufacturers of active pharmaceutical ingredients (APIs) and fragrances 

– gain two advantages: reduction of production costs and a more sustainable process. 

Development, production and distribution of in vitro-diagnostics for analytical purpose 

and the distribution of medical products. 

DIZG German Institute for Cell and Tissue Replacement engages in cell and tissue 

preservation as well as in cell and tissue replacement, and provides tissue preparations 

of human origin to clinics, teaching and research organisations. Further service is culturing 

of skin cells (keratinozytes) for serious burns and other skin defects not healing 

well or affecting large areas. DIZG supplies cell cultures to help avoid experimentation 

with animals e.g. in the cosmetics industry. 

Contract research and contract manufacturing using bacteria, yeasts and fungi. 

Innovative company engaged in development, production and marketing of specialized 

microcapsules for bio- and medical technology - Development and production of 

novel DNA-Purification-Kits with proprietary technology - Production and marketing of 

microcapsules (LUMiTainer), microbeads and cell based sedimentation standards for 

blood analysis (Sedi-Val ESR standards) - Encapsulation of cells - Contract analysis for 

characterization of microcapsules, porous membranes and hollow fibres. 

Handling with research and development of ecological products its process of development 

also its production and marketing - Production and refinement of plantingredients 

- Operate an analytical laboratory of renewable resources and chem. Analysis. 

Dr. Roelleke is specialized on the identification of microorganisms, particularly in the 

area of food safety. Furthermore, Dr. Roelleke is authorized expert on paternity tests for 

courts and the private sector. 

cellserve.de 

celltrend.de 

chemicell.com 

chipron.com 

chiracon.de 

cmz-assay.com 

codon.de 

congen.de 

cyano-biotech.com 

dendropharm.de 

dexlechem.com 

diaglobal.de 

dizg.de 

drgoetz.de 

lerche-biotec.com 

dr-otto-gmbh.de 

dr-roelleke.de 

50




Drug Response Dx GmbH 

E.R.D.E.-AAK-Diagnostik GmbH 

EMP Biotech GmbH 

Epigenomics AG 

Epinamics GmbH 

Epiontis GmbH 

Epo Experimentelle 

Pharmakologie & Onkologie 

GmbH 

Eternygen GmbH 

Eurovir Hygiene-Institut/Dr. 

Thraenhart 

EVESTRA GmbH 

F.A.T. Forschungsinstitut für 

Antioxidative Therapie GmbH 

Fermtec GmbH 

FILT Lungen- und 

Thoraxdiagnostik GmbH 

Formula GmbH 

G&Life SpA 

GA Generic Assays GmbH 

Gene Analysis Service GmbH 

GenExpress Gesellschaft für 

Proteindesign GmbH 

DRDx makes drug response predictable: Challenge and necessity of personalized 

medicine and individualized therapies demand for convincing and reliable companion 

diagnostics. The first field of activity of DRDx is Rheumatoid Arthritis (RA). The goal 

of our company is the technical and clinical validation of an IVD test kit for the reliable 

prediction of therapy response to TBAs ahead of treatment. 

E.R.D.E.-AAK-Diagnostik GmbH is a laboratory that offers antibody testing for commercial 

purposes. 

Production of fluorescent dyes and chemiluminescent reagents. Contract chemical 

synthesis of small molecules. Contract labeling and purification of proteins, antibodies 

and oligonucleotides. Production of size-exclusion gels, columns and filter plates. Production 

of high quality reagents for DNA synthesis. 

Development and commercialization of innovative molecular diagnostic test products 

based on DNA methylation for cancer screening and for cancer specialty applications. 

Epinamics GmbH, a newly established Berlin based pharmaceutical research and 

development dedicated company, is owner of a proprietary film forming formulation 

technology platform, the ?Invisible Patch? system. The system is offering a broad basis 

for the development of formulations for treatment of dermatological diseases as well as 

for the development of transdermal systems. 

Establishing methylation fingerprinting as Gold Standard for quality control in Regenerative 

Medicine and Immunomonitoring. 

The pharmaceutical and oncological testing of new drugs or treatment concepts for 

cancer is a specialized market segment. Using the equipment available, all experimental 

techniques can be carried out in first-rate quality. That means that EPO is an attractive 

partner for the drug development section of large pharmaceutical companies, for 

partners from the Biotech industry and for research institutions. 

Eternygen is a Berlin based start up founded in June 2012 focusing on research, development 

and marketing of innovative drugs using a network of renowned scientists 

and contract research organizations. The main focus of Eternygen´s development and 

core competences of its founders are research and development of new drugs for 

dietary-related metabolic diseases with dramatically increasing prevalences in the last 

decades. 

Laboratory service for testing the efficiency of products against viruses (virucides) and 

of processes for inactivating or eliminating viruses (virus safety). 

EVESTRA is a newly founded biotech company focusing on developing female health 

products. The companies expertise resides with steroid chemistry and biology. EVES- 

TRA’s product pipeline includes products for contraception, hormone replacement therapy, 

gynecological disorders and hormon dependent cancers. 

Measuring instruments and kits for evaluating the antioxidant properties and the degree 

of oxidative damage in biological substrates. 

Development of non-alcoholic beverages, beers and beer mix beverages, lactic acid 

fermentation, innovative foods and beverages and auxiliary substances for the food 

industry. 

Development of innovative, non-invasive diagnostic methods in the area of respiratory 

diseases and allergies. 

Galenical development of liquids and solid formulations Lyophilization Technolgy also 

apllicable for biochemical products Granulation, drying and coating using fluid bed 

drying-technology, tabletting Development and validation of analytical methods including 

UPLC Stability testing (ICH / GMP related to on going) Import of medicinal poducts 

from non-EU-countries, manufacturing, quality control (re-test) and release for market 

in accordance with §16 AMWHV for medicinal products and clinical supplies GMP-certificat 

/ Manufacturing license in accordance with §13 AMG. 

G&life provides personalized strategies based on genetics. The life-science company 

is made up of a multi-disciplinary team combining expertise in genetics, nutrition, sport 

and engineering to develop products and services aimed at improving the quality of 

life. 

Development, manufacturing and distributing of in vitro-tests, focussing on autoimmune 

diseases, hereditary and infections diseases. 

Gene Analysis Service is specialized on genetic testing of a number of rare hereditary 

diseases and provides nucleic acid based molecular biological services like PCR and 

custom DNA sequencing for healthcare providers and research institutes worldwide. 

GenExpress is a flexible company providing services in molecular biology. For over a 

decade we have successfully worked for customers in clinical laboratories, research 

institutions and the industry. We offer cloning of PCR targets, preparation of synthetic 

genes, expression of proteins, evaluation of LightCycler ® assays, furthermore production 

of internal controls and standards for Real Time PCR systems, also cloning, expression 

and purification of proteins. 

drdx.de 

aak-diagnostik.de 

empbiotech.com 

epigenomics.com 

epinamics.com 

epiontis.com 

epo-berlin.com 

eternygen.com 

eurovir.de 

evestra.com 

antioxidant-research.eu 

fermtecgmbh.de 

filt.de 

formula-pharma.de 

glifecompany.com 

genericassays.com 

gene-analysis-service.de 

genexpress.de 

51




GILUPI GmbH 

GlucoMetrix PVS GmbH 

Glycon Biochemicals GmbH 

Glycotope GmbH 

GlycoUniverse GmbH 

GILUPI is a medical diagnostics company with an initial focus on the prenatal and cancer 

market. The company is developing an innovative new diagnostic product based 

on nanotechnology. Our goal is to catch specific cells, which can be found only in very 

low concentration in the blood. The first application for our new nanosensor device will 

be prenatal diagnoses of chromosomal aberration out of maternal blood. The second 

application will focus on the early diagnosis of cancer. 

The GlucoMetrix AG focuses on the early detection and management of diabetes 

mellitus-aftermath. At the foreground of research and development is the enhancing 

the quality of life of diabetics. In addition, the life science company develops some 

IT-based diagnostic procedures and medical devices as well as biopharmaceuticals 

and other highly effective products in order to raise the quality of life of diabetics sustainably. 

Production of carbohydrate components used for the synthesis of new pharmaceutical 

compounds or diagnostics. 

Glycotope is a leading company in glycomics and immunotherapeutics. It has developed 

novel therapeutic antibodies and unique platform technologies to optimize the glycosylation 

of new biological entities. Glycotope Biotechnology, with 25 years of experience 

in GMP-production, enables us to offer the entire process of biopharmaceutical 

development with a dedicated focus on our unrivalled expertise in protein glycosylation 

from the gene to production and fill & finish of clinical grade material. 

GlycoUniverse GmbH & Co KGaA is a technology spin-off of the Max Planck Institute of 

Colloids and Interfaces. Registered on 10th October 2013, the company deals with the 

automated development and synthetic production of complex sugars and is seeking 

customers and collaboration with leading scientific institutes in Europe and world-wide. 

gilupi.com 

glucometrix.de 

glycon.de 

glycotope.com 

glycouniverse.de 

Götz Protein Engineering Offering a wide range of protein technology up to the final purified protein. goetz-protein-engineering. 

de 

HealthTwiSt GmbH 

HF Biotec Berlin GmbH 

Hybrotec GmbH 

ICI GmbH 

Icon biotech 

IDrug GmbH 

Ifp Institut für Produktqualität 

GmbH 

IGV Institut für 

Getreideverarbeitung GmbH 

IKDT Institut Kardiale Diagnostik 

und Therapie GmbH 

HealthTwiSt is a service provider for “Genetic Contract Research” in the fields of Functional 

Genomics, Epigenetics, Proteomics or Functional Food / Nutriceuticals. In particular, 

HealthTwiSt is offering access to extensively characterized human subjects and 

samples as well as prospective studies in twins, together with know-how in the analysis 

of complex genetic traits. Furthermore, database development, data management and 

statistical analyses for clinical projects are provided. 

Development, selling and operating of digestion plants using liquid substrates of industrial 

and agricultural provenience, Development and operating of combined plants to 

upgrade biogas into bio methane useable in public gas grids with parallel production 

and selling of high quality PCC, Development of innovative biotechnological processes 

and plants. 

Hybrotec GmbH is specialized in the development of monoclonal antibodies and immunoassays 

(preferably homogenous assays) as customs service. Our main focus lies 

on antibodies binding low molecular weight substances (e.g. toxins, fluorophores, hormones) 

as well as antibodies against novel proteins. 

ICI – immunochemical intelligence gmbh – is dedicated to the development and production 

of innovative immunoassay components and kits for research use. Their goal 

is to provide individual solutions, exactly tailored to the client’s needs and to create 

lasting relationships by providing outstanding services and high quality products to 

demanding clients. 

Icon biotech is an innovative biotechnology company, which uses the extraordinary 

characteristics of Ciliates for the development of bio-analytical and toxicological model 

systems. 

IDrug supports business strategies with innovative methodologies in analytical and biopharmaceutical 

chemistry 

Ifp Institut für Produktqualität is a laboratory and competence centre for state-of-the-art 

food, drinking water and pharmaceutical analysis. The accredited and GMP-certified 

company focuses on comprehensive services for the food and pharma industry. An 

additional core competence of ifp is the development and production of innovative 

diagnostics comprising the real-time PCR kits of the brand “mericon” (QIAGEN), vitamin 

tests in microtiter plate format, enzymatic microtiter plate kits for sugars/acids, and 

allergen tests in lateral flow and ELISA formats. 

The range of services offered by the Biotechnology Division of the private research 

IGV GmbH institute is based on 25 years of experience in R&amp,D for the cultivation 

of phototropic micro-organisms. Excellent, world-wide contacts to biomass producers, 

food producers, to the pharmaceutical and cosmetics and energy industry provide the 

fundament for innovative, market-oriented developments. In focus are development of 

photo bioreactor technology and active substances from algae. 

IKDT was founded in August 2002 in Berlin-Steglitz and is one of the leading laboratories 

on Viral Infections of Heart Muscle Tissue and Dilatated Cardiomyopathy (DCM) in 

Germany. IKDT lab is performing a comprehensive molecular diagnostic examination of 

endomyocardial biopsies as one of a limited number of specialized cardiological labs 

worldwide. Its service enables physicians firstly to start an efficient, pathophysiologically 

based causal therapy. 

healthtwist.de 

hf-biotec.com 

hybrotec.com 

ici-diagnostics.com 

icon-biotech.com 

idrug.de 

produktqualitaet.com 

igv-gmbh.de 

ikdt.de 

52




ILBC GmbH 

ImaGenes GmbH 

In.vent DIAGNOSTICA GmbH 

inbion GmbH 

Innovative Optische Meßtechnik 

GmbH 

Institut für Medizinische 

Molekulardiagnostik (IMMD) 

GmbH 

Institut für Molekular- und 

Systemmedizin I.M.S.M. GmbH 

InterMune GmbH 

InVivo Biotech Services GmbH 

InvivoContrast GmbH 

JPK Instruments AG 

JPT Peptide Technologies GmbH 

KNAUER - Wissenschaftliche 

Gerätebau Dr. Ing. Herbert 

Knauer GmbH 

L.U.M. Gesellschaft für 

Labor-, Umweltdiagnostik & 

Medizintechnik mbH 

labfolder GmbH 

Research, consulting, production, trade & services in the areas biology, molecular biology 

and protein chemistry - Expression and production of antimicrobial peptides. 

RZPD spin-off, today part of Source BioScience plc, a premier service center for genome 

research and healthcare in Europe, provides one of the largest clone collections 

in the world via its clone search engine GenomeCube ® . Certified Service Provider for 

illumina Next Generation Sequencing services and comprehensive microarray application 

on Affymetrix, Agilent, and NimbleGen platforms. ISO 9001:2008 certified. 

in.vent DIAGNOSTICA GMBH is a biomedical company. We are focused on the project-oriented 

provision, processing and distribution of biological raw material for development 

and production of diagnostics and control material. We are your reliable 

partner for the customised development of assays for medical in vitro-diagnostics. 

inbion GmbH provides services to support research in the interface between university, 

students and industry. For companies, we provide the benefit of outsourcing projects 

quickly and cost-efficiently to competent teams. Cooperation with research groups in 

the university is also facilitated, so that targeted knowledge transfer can take place 

here. 

Fluorescence Assay Solutions and Instrumentation (Microplate Readers). 

Gene tests for prenatal, predictive and tumor -diagnostics. 

Scientific-practical works in the area of System medicine with the purpose of the patenting 

of new treatment methods, e.g. to the treatment of diabetes. International cooperation 

in this area. 

InterMune is a biotechnology company focused on the research, development and 

commercialization of innovative therapies in pulmonology and fibrotic diseases. In 

pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary 

fibrosis (IPF), a progressive and fatal lung disease. 

As a contract manufacturing company (CMO) Invivo offers a wide range of services: 

the development and production of monoclonal antibodies and recombinant proteins 

for diagnostic and pre-clinical use (endotoxin-free antibodies and compliant documentation), 

cell line development and transient transfection. We are an ISO9001:2008 certified 

company. 

InvivoContrast provides globally high quality MRI (Magnetic Resonance Imaging) contrast 

agents and professional support for preclinical imaging in academic and commercial 

institutions. 

JPK Instruments AG is a world-leading manufacturer of nanoanalytic instruments - particularly 

atomic force microscope (AFM) systems and optical tweezers - for a broad 

range of applications reaching from soft matter physics to nano-optics, from surface 

chemistry to cell and molecular biology. From its earliest days applying atomic force 

microscope (AFM) technology, JPK has recognized the opportunities provided by nanotechnology 

for transforming life sciences and soft matter research. 

JPT is an ISO 9001:2008 certified provider of innovative peptide products and services 

and a partner for research projects focusing on the development of novel immune 

therapeutics & diagnostics, profiling of various enzyme classes and proteomics. JPT 

has developed a portfolio of proprietary technologies and a series of unique products 

which support a worldwide customer base. Since 2011 all catalog products such as 

peptide microarrays & peptide pools are avalaible through an online shop. 

KNAUER UHPLC and HPLC systems as well as columns are used in research and 

development, quality control and production plant laboratories around the world. Customers 

are typically governmental and industrial organizations as well as universities. 

Fields of application are wide-ranging and include pharmaceutical and medical research, 

analysis of foodstuffs and cosmetics, as well as environmental analysis. With 

our biochromatography solutions we focus on high resolution separations. 

Analysis, diagnosis and sensor technology as well as stability, rheology and segregation 

behavior of dispersions. 

labfolder is a digital notebook and collaboration platform for laboratory research. As a 

viable alternative to traditional paper-based laboratory notebooks, labfolder allows scientists 

to document and organize their research, plan their experiments and collaborate 

with others digitally. The software provides an intuitive user interface and is compliant 

with the rules of Good Scientific Practice (GxP), including full audit trail and digital 

signatures for maximum intellectual property protection. labfolder is also available on 

all mobile devices operating under Android and iOS, allowing scientists to access and 

manage their data from everywhere. labfolder is free for individual scientists and small 

groups and offers advanced functions for large research groups and enterprises for 

a monthly fee. 

mobiclup.de 

imagenes-bio.de 

inventdiagnostica.de 

inbion.de 

iom-berlin.de 

immd.de 

intermune.de 

invivo.de 

invivoContrast.com 

jpk.com 

jpt.com 

knauer.net 

lum-gmbh.de 

labfolder.com 

53




Labor Berlin – Charité Vivantes 

Services GmbHLabor Berlin – 

Charité Vivantes GmbH 

LGC Genomics GmbH 

Labor Berlin Services is the service subsidiary of Europe’s largest hospital laboratory 

for clinical pathology and offers complete solutions for any kind of testing for the ivd 

industry, CROs, the pharmaceutical industry, life science companies and research facilities, 

while Labor Berlin is the exclusive laboratory partner of Charité - Universitätsmedizin 

Berlin and the Vivantes Network for Health. Labor Berlin and Labor Berlin Services 

both perform over 35 million analyses in clinical pathology per year and provide 

the diagnostic services for approximately 400.000 in-house patients a day and some 

one million out-patients per year. 

LGC Genomics is the division of LGC with specific expertise in high quality, cutting-edge 

genomic and related services and products. LGC Genomics delivers:- Next 

generation sequencing services- DNA sequencing- Genomics services- Nucleic acid 

extraction services- DNA extraction products. LGC is an international science-based 

company and market leader in analytical, forensic and diagnostic services and reference 

standards (lgc.co.uk). 

laborberlin.com 

lgcgenomics.com 

LGC GmbH Production of calibration substances for purity testing of drugs. mikromol.de 

Life Glimmer 

Limetec Biotechnologies GmbH 

Lipidomix GmbH 

MagForce AG 

Marinpharm GmbH 

MedInnovation GmbH 

Medipan GmbH 

MerLion Pharmaceuticals GmbH 

Merz Pharmaceuticals GmbH / 

Standort Potsdam 

Metabolomic Discoveries GmbH 

Metanomics GmbH 


MetrioPharm AG 

Mfd Diagnostics GmbH 

Life Glimmer is a customer-oriented consulting and contract research company with 

the goal of providing the biotechnological, biomedical and environmental research 

communities an efficient way to outsource scientific modeling and computing needs. 

The core competence lies in the development of high-speed and high-quality proof 

systems for the detection of pathogens, as well as in the allelic discrimination of hereditary 

diseases. All products are marked with the CE-Certificate. The second area 

of expertise is the creation of communication networks which connect out-patient and 

hospital patient treatments, intensify data exchange and provide information to all health 

institutions, thus establishing partner relationships between them. 

LC/MS/MS based high trouput analytic of lipid mediators and metabolites. Analytical 

method development, analytical support for LC/MS/MS in life science, food safety, forensic 

science. 

MagForce AG is a leading medical technology company focusing on nanomedicine 

in oncology. The company’s proprietary procedure, NanoTherm ® therapy, enables the 

targeted treatment of solid tumors through the intratumoral generation of heat via activation 

of magnetic nanoparticles. NanoTherm ® , NanoPlan ® , and NanoActivator are 

components of the therapy and have received EU-wide regulatory approval as medical 

devices for the treatment of brain tumors. 

Development and marketing of genetically altered cell lines on the basis of new fluorescence 

markers. Generation of stably transfected fluorescent cell lines. 

MedInnovation GmbH has developed a new method and a special ESR-analyser, which 

for the first time allows a simple routine laboratory test for evaluation of functional characteristics 

of plasma proteins and further opens a reliable possibility for cancer diagnostic, 

named MMS-technology (mobility of molecular structure). 

Development, manufacturing and international distribution of radioactive (125J-IRMA) 

and non-radioactive (Elisa) in vitro-diagnostic tests, covering the field of Autoimmunity, 

mainly in Thyroid and Diabetes Typ 1 and automated interpretation of cell-based immunofluorescence 

tests by the AKLIDES system. 

The business purpose of the Company is the research, production, optimization and 

the development by way of pre-clinical as well as clinical trials of new molecules for the 

treatment of infectious diseases. 

Merz is one of the leading research-based health care companies. Merz Pharmaceuticals 

has achieved a leading position in Alzheimer’s research with the world’s first 

drug for the treatment of moderate to severe Alzheimer’s disease. With high quality 

products from tetesept ® and Merz Spezial ® , Merz is making a key contribution to health 

and wellbeing. 

Metabolomic Discoveries is an analytical service and research company. We provide 

mass spectrometry based metabolite profiling and fingerprinting of biological material, 

as well as single compound measurements. 

Metabolite Profiling for identification of gene function relationship in plants, metabolite 

biomarkers and metabolic networks. 

Identification of metabolic biomarkers for pharmacology, toxicology, diagnostic and 

nutrition. 

MetrioPharm AG develops innovative therapies for infectious diseases on the basis of 

new and innovative medicines. 

The mfd Diagnostics GmbH (BT Luckenwalde) is a life science research and development 

company for diagnostic and therapeutic application of innovative laser technologies. 

The main advantages of the developed technologies are the non-/minimally-invasive 

measurement methods, the non-artificial approach and the possibility of real-time 

measurement. Therefore, those are promising tools for the diagnosis and therapy monitoring 

in the neurological practice and in the perinatal surveillance. 

lifeglimmer.com 

limetec-biotechnologies.de 

lipidomix.de 

magforce.com 

marinpharm.com 

medinnovation.de 

medipan.de 

merlionpharma.com 

merz.de 

metabolomicdiscoveries. 

com 

metanomics.de 

metanomics-health.de 

metriopharm.com 

mfd-diagnostics.com 

54




MicroDiscovery GmbH 

Microparticles GmbH 

Minerva Analytix GmbH 

Minerva Biolabs GmbH 

mivenion GmbH 

MLB Mikrobiologisches Labor 

GmbH 

Molnar-Institut für angewandte 

Chromatographie 

MOLOGEN AG 

moloX GmbH 

MRI.TOOLS GmbH 

Myelo Therapeutics 

Nano Access Technologies Ltd. 

Nanolytics Gesellschaft für 

Kolloidanalytik mbH 

Nanopartica GmbH 

MicroDiscovery GmbH is a leading provider of high quality software for biomolecular 

research, innovative diagnostics and personalised medicine. The company is ISO 9001 

certified and has a strong track record in creating software systems in accordance with 

relevant regulatory directives for the life science and IVD industry. Customised services 

ranging from biostatistical data analysis to bioinformatical design and support of complex 

research projects complete the product line of MicroDiscovery. 

Development, manufacture, surface modification and characterization of mono-disperse 

polymer particles in the nano- and micrometer range. In addition to classic polystyrol 

and polyacrylate-based polymer particles, microparticles GmbH has launched new 

melamine resin particles on the market with exceptional chemical and physical qualities. 

The main areas of application are in particle measurement technology, medicine, 

biochemistry and microelectronics etc. 

Minerva Analytix GmbH is a leading analytical service lab for the control of microbial 

contamination. Our core competence lies in the control of mycoplasma, bacteria and 

viruses in cell cultures and biopharmaceuticals 

Minerva Biolabs develops and produces IVD kits for diagnosing pathogens and for 

contamination control, especially mycoplasma in cell cultures and biopharmaceutical 

products. Minerva Biolabs is also active in ensuring water quality with sensitive processes 

for detecting legionella. Our distributors ensure that our products are available 

worldwide, quickly and at a good price. 

mivenion is a life-science company founded in Berlin aiming on the development and 

commercialization of diagnostic and therapeutic products. The company is built on two 

innovative technologies: the fluorescence camera system Xiralite for diagnostic imaging 

of early rheumatoid arthritis and a proprietary bioactive polymer drug development 

platform. Xiralite is mivenion´s first product on the market. 

Accredited test laboratory for drinking water, clean rooms, sterility, bioburdens, D-PL- 

13398-01-00, EN 17025. Accreditation according to VDI 6022. 

Molnar-Institute, established in 1981, offers you a complete scientific and technical 

service for all problems concerning Quality by Design (QbD) for HPLC-methods. We 

develop for you the Design Space for your HPLC-separation and establish Critcal Quality 

Attributes (CQA’s). We offer detailed DryLab-courses and show you, how to develop 

robust methods in the Design Space and how to save time. We supply and implement 

the DryLab-software and train your coworkers. We assist you in automated method 

development processes and support you in the selection of proper instruments, their 

installation and use. 

MOLOGEN AG is a biopharmaceutical company based in Berlin and specializes in 

the development of novel DNA-based medicines against cancer and vaccines against 

infectious diseases. The proprietary platform technologies MIDGE ® and dSLIM ® build 

the foundation for all business activities. The company was founded 1998 and was one 

of the first biotechnology companies to go public. 

moloX GmbH is a company focusing on custom protein production in bacterial and insect 

cell expression systems and subsequent protein purification to ultra-high purity. On 

customer demand a team of experts can perform protein crystallization experiments 

and determine the 3D structure of target proteins by X-ray crystallography. 

MRI.TOOLS´s main focus is the development, sales and services of innovative hardware 

and novel technology for magnetic resonance imaging (MRI), computed tomography 

(CT) and positron emission tomography (PET). Our product portfolio encompasses 

enabling radiofrequency (RF) coils tailored for a broad range of applications, devices 

designed for reliable cardiac gating of imaging plus accessories that will make your 

daily life more comfortable. MRI.TOOLS is also very proud to offer consulting services 

such as validation and certification of medical devices. 

Myelo Therapeutics GmbH develops innovative treatments in areas of high unmet medical 

needs. 

The company addresses the combined access to key technologies such as life science 

and nanotechnology. As a first product, a low cost AFM for operation with so-called active 

cantilevers has been developed. Besides this, functionalized cantilevers for future 

biosensors are another focus of the company. 

We are a contract laboratory specializing in the physico-chemical characterization 

of pharmaceutical proteins, biopolymers, nanoparticles and colloidal systems. Our 

core-competences are Analytical Ultracentrifugation, in combination with Static and 

Dynamic Light Scattering as well as spectroscopic (CD, fluorescence) and thermodynamic 

techniques (ITC, DSC). 

Nanopartica GmbH optimizes existing products of other companies, but are also developing 

new products and materials. In particular, companies in surface-, bio-, and medical-technology 

can benefit from nanopartica. By means of functionalized polymers, we 

can encapsulate guest molecules (drugs, dyes, vitamins), particles (gold, silver, platinum), 

or ions. This will indirectly change the guests properties and expands its scope. 

microdiscovery.de 

microparticles.de 

minerva-analytix.com 

minerva-biolabs.com 

mivenion.com 

mikroberlin.de 

molnar-institute.com 

mologen.com 

molox.de 

mritools.de 

myelotherapeutics.com 

nano-access.com 

nanolytics.de 

nanopartica.com 

55





NovaBiotec ® Dr. Fechter GmbH 

NOXXON Pharma AG 

OakLabs GmbH 

OctreoPharm Sciences GmbH 

Omeicos Therapeutics GmbH 

OpTricon 

Entwicklungsgesellschaft für 

optische Technologien mbH 


ORGANOBALANCE Medical AG 

ovalehn GmbH 

Pentracor GmbH 

Peptides&elephants GmbH 

PharmaSol GmbH 

PlasmaChem GmbH 

As a technology and service provider to the biopharmaceutical industry nanoPET focuses 

on the R&D, production as well as marketing of innovative drug substances for 

diagnostic imaging based on novel nanoparticular materials. nanoPET offers consulting 

and contract research services, preclinical contrast agents (MRT, CT, US, NIR, PET) as 

catalog items and pursues the preclinical development of its patented core technology 

of inorganic nanoparticle PET tracers. 

Microbiological and chemical investigations, in particular of soil, water and air samples, 

planning / inspection of sanitation, in particular analytics and sanitation support for 

mould and dry rot, incl. education in this field. Delivery of production auxilliaries and 

support for biogas plants with biological treatment processes incl. application, insulation 

and preservation of enzymes. Research, development and marketing of test kits 

for breweries and malthouses. 

NOXXON Pharma is a biopharmaceutical company pioneering the development of 

a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are the 

chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a 

diversified portfolio of clinical stage Spiegelmer therapeutics: Spiegelmer ® NOX-E36, 

Spiegelmer ® NOX-A12, Spiegelmer ® NOX-H94. The Spiegelmer platform provides the 

Company with powerful and unique discovery capabilities, which have generated a 

number of additional leads under preclinical investigation. Located in Berlin, Germany, 

NOXXON is a well financed mature biotech company with a strong syndicate of international 

investors, approx. 60 employees and a highly experienced management team. 

OakLabs provides the most flexible products and services for large scale custom SNP 

genotyping on the market. OakLabs offers several formats for analysing a variable number 

of SNPs in any sequenced organism. 

OctreoPharm Sciences GmbH is a clinical development company focusing on diagnostic 

radiopharmaceuticals. 

OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing 

a new Mode of Action for the treatment and prevention of atrial fibrillation. OMEICOS' 

novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 

fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic 

drugs, OMEICOS' substances activate an endogenous cardio-protective 

signaling pathway that not only stabilizes the heart rhythm but shall provide curative 

effects to the diseased organ by preventing its electrical and structural remodeling. 

OpTricon develops and produces mobile readers for quantitative analyzes of Immunoassays 

for Point-of-Care-diagnostics, especially Lateral Flow Assays (LFA). Additional 

business segments are components and Systems for signal transmission and sensors 

for lbioanalytics. opTricon develops the devices in partnership with the customers 

and works as OEM-suppliers and is certified by TÜV Rheinland according EN ISO 

13485:2003+AC: 2007 and EN ISO 9001:2008. 

ORGANOBALANCE is a company specializing in microbial strain development and 

screening. As a R&D contractor ORGANOBALANCE develops new biological products 

in the areas of nutrition, personal care and health care. The company draws on its own 

collection of microbial strains suitable for food applications and its OASSYS ® bioassay 

systems. In the field of “metabolic engineering” ORGANOBALANCE exploits Saccharomyces 

cerevisiae yeast for synthesis of substances for the industrial and pharmaceutical 

industry. 

ORGANOBALANCE Medical AG funds and promotes the research and development 

of novel therapies based on specific probiotic cultures, aiming to develop active substances 

and mechanisms for innovative medicinal products and medical devices, as 

well as offer new therapeutic concepts for hitherto inadequately treatable indications. 

Production and application of specific recipes -containing IgY for diagnostics and oral, 

passive immune therapy. 

In the case of cardiac infarction, C-reactive protein (CRP) results in an increase of the 

primary damage. Based on a new prototype, the company Pentracor GmbH aims to 

develop an adsorber for therapeutic reduction of CRP, lead it to approval, establish its 

certified production and market the product after clinical validation. 

Custom synthesis of peptides and peptide libraries Development parallel Synthesis 

technologies Distributor of Peptide Synthesis Automation. 

Modification of ingredients or introduction of new metabolic pathways in plants with 

gene-technology methods. 

PlasmaChem GmbH is an innovative R&D and manufacturing company specializing in 

nanomaterials, plasma- and ultra-thin film technologies. The company manufactures 

nano-coated medical implants (stents), nanomaterials, additives for metal plating (applied 

e.g. by Siemens AG), new additives to engine oils on the base of nanodiamonds 

and other industrial nanoproducts. 

nanopet-pharma.com 

novabiotec.de 

noxxon.com 

oak-labs.com 

octreopharmsciences.com 

omeicos.com 

optricon.de 

organobalance.com 

organobalancemedical.com 

ovalehn.de 

pentracor.com 

peptides.de 

pharmasol-berlin.de 

plasmachem.com 

56




PolyAn, Gesellschaft zur 

Herstellung von Polymeren für 

spezielle Anwendungen und 

Analytik mbH 

Preclinics Gesellschaft für 

präklinische Forschung mbH 

Predemtec GmbH 

ProBioData GmbH 

ProBioGen AG 

ProteaImmun GmbH 

PROTEKUM - Umweltinstitut 

GmbH, Oranienburg 

Proteome Factory AG 

Provitro GmbH 

Rapidozym Gesellschaft 

für Laborhandel und DNA 

Diagnostika mbH 

RENESA UG 

(haftungsbeschränkt) 

RiNA GmbH 

RIPAC-LABOR GmbH 

Roboklon GmbH 

PolyAn is specialised in Molecular Surface Engineering (MSE). Using our surface modification 

expertise PolyAn optimises the performance of analytical systems by improving 

the signal-to-noise ratio as well as the reproducibility of consumables for multiplex diagnostics, 

LifeScience research and screening applications. PolyAn?s product portfolio 

includes functionalised microarray slides, microparticles for multiplex bead arrays and 

functionalised membranes for medical diagnostic applications. 

Preclinics is a commercial cooperation partner for preclinical research and development. 

As a competent, creative and experienced partner preclinics investigates pharmaceutical 

substances, therapeutic methods and proceedings as well as medical 

products during the preclinical phase. Additional we provide custom antibody production 

in llama, goat, sheep, rabbit and other species. 

Predemtec GmbH is a company focused on the research, development and manufacture 

of innovative diagnostic tests for use in the detection of dementia-related risk 

factors. The goal has been to make the early and reliable diagnosis of various dementia-related 

illnesses a reality through the use of our innovative diagnostics tests. 

BioProcessDB is a database solution for bioprocess R&D. It's designed to become the 

linking tool in your information process and to integrate the data i. e. from the SCADA 

system, the sample data management and the strain management. 

ProBioGen is a Contract Development and Manufacturing Organization (CDMO) and 

Technology Provider, with extensive expertise in cell line engineering, process development 

(upstream- and downstream process) and GMP manufacturing of biopharmaceuticals. 

Offering state-of-the-art contract development and manufacturing services 

as well as access to proprietary cell lines (AGE1.cell lines ® ) for the manufacturing of 

biopharmaceuticals and vaccines. The company possesses the manufacturing authorization 

from the competent authority and meets the quality standards required by the 

EMA and the FDA guidelines. 

ProteaImmun is a specialized proteomic company providing purified human proteins, 

antibodies and ELISAs. Our proteins are designed for structural and functional studies 

of proteases screening and evaluation of protease inhibitors and modulators. Furthermore 

we develop highly sensitive ELISA kits and antibodies. Our Focus: MMPs, 

ADAMTs, HtrAs. ProteaImmun produces a unique range of recombinant proteases for 

medical and pharmaceutical research. The main focus is on human Matrix Metalloproteases 

(MMPs), ADAMTS and HtrA proteins which play an important role in neurodegenerative 

disease, ancer and arthritis. Customer Service: ProteaImmun provides 

activity analysis by zymography adapted for MMPs. 

We plan to eliminated fluid und solid waste products in a manner which is compatible 

with environment protection. Our methodology is largely based on painstaking analysis. 

We use modern equipment and scientific methods. Protekum offers high-quality products 

and services in environmental analysis redevelopment. 

Biomarker & target discovery, validation, analysis of food and ingredients, absolute 

quantification of proteins and peptides, sequencing and characterization of proteins 

and antibodies (CDR), 2DE and LC-MS based proteomics studies, pharmacokinetics, 

pharmaco, immuno and membrane proteomics, protein identification, characterization 

of proteins and peptides (PTMs, e.g. phosphorylation, glycosilation), quality control, 

mass determination, N-terminal amino acid sequencing, silver staining kit etc. 

Provitro combines more than ten years of experiences in commercialisation of cell 

culture technologies, Tissue Microarrays and immunohistochemical analyses with the 

scientific expertise of the Pathological Institute of the Charité, Berlin. Based on a quality 

management system according to ISO 9001:2008, we provide our customers not only 

with high-quality products, CE marked in vitro-diagnostics and state-of-the-art services 

but also with individual solutions for their specific requests. 

Expertise of cell biologists cell manufacturing and clean room technology specialists. 

Focuses on clinical stem cell product development portfolio are stroke, myocardial infarction 

and plastic surgery. 

Manufacturing and distribution of rapid tests, mainly for medical purposes (Point of 

Care Testing). 

RiNA has developed systems for cell-free protein biosynthesis based on pro- and eukaryotic 

cell lysates. A synthesis service is realised in RiNA’s own laboratories and 

complements the EasyXpress Kits (Qiagen). The purchase of Roche´s RTS-products 

enables RiNA now to be a key player in the field of cellfree biosynthesis with a large 

variety of products. Another research focus is the development of aptamers (DNA and 

RNA) for biosensors. 

RIPAC-LABOR offers high-quality diagnoses of bacterial infections, particularly in poultry, 

pigs and cattle, but also in other farm and domestic animals. The company uses 

pathogen differentiation to provide quick and effective methods for fighting pathogens. 

It performs resistance tests and epidemiological analyses and also focuses on producing 

herd-specific vaccines. 

Distribution, Marketing and Development of Products for Molecular Biological Research 

and Genetic Engineering. 

poly-an.de 

preclinics.com 

predemtecDX.com 

probiodata.de 

probiogen.de 

proteaimmun.net 

protekum.de 

proteomefactory.com 

provitro.de 

rapidozym.de 

renesa.de 

rina-gmbh.eu 

ripac-labor.de 

roboklon.de 

57




ROVALAB GmbH 

Royal Biotech GmbH 

Scienion AG 

Sepiatec GmbH 

Seramun Diagnostica GmbH 

SGS INSTITUT FRESENIUS 

Berlin GmbH & Co. KG 

SIFIN Institut für Immunpräparate 

und Nährmedien GmbH Berlin 

Signature Diagnostics AG 

Silence Therapeutics AG 

SINA Science Services GmbH 

SLM- Speziallabor für 

angewandte Mikrobiologie GmbH 

Sopat GmbH 

STRATEC Molecular GmbH 

Strix Diagnostics GmbH 

Surflay Nanotec GmbH 

Our Master Mixes for QPCR, Standard-, Hot Start- and High Fidelity PCR as well as our 

high quality critical raw materials and reagents such as DNA Polymerases and dNTPs 

are designed to help you successfully and rapidly solve your scientific and manufacturing 

tasks. 

Royal focuses on developing, manufacturing and marketing innovative kits, portable 

or micro-structured systems, and the next generation of diagnostic chips for near real-time 

environmental, food safety, disease and laboratory diagnostics. 

Scienion is a life science company in the markets of dispensing systems and microarray 

technologies. The product portfolio comprises hardware, consumables and services. 

Scienion’s leading product is the sciFLEXARRAYER dispensing system, available 

in a product line of six size versions. The dispenser allows the aspiration of ultra low 

liquid volumes from different reservoirs and non-contact micro drop delivery in the 

picoliter to microliter range onto a variety of carriers. 

Production, development and sales of automated HPLC machines for high-throughput 

purification and fractioning of complex substance compounds. 

Seramun offers peptide synthesis, purification and conjugation of proteins, production 

of antibodies, customer research, in vitro-Diagnostics. We focus on the development 

and production of enzyme immunoassays for diagnosis of viral and bacterial infections 

and autoimmune diseases of the gastrointestinal tract, the development of multi-parameter 

assays as microtitre plate assays and as membrane immunoassays, as well as 

development of ready-to-use substrate solutions and for protein stabilizers. 

Analytical laboratory services and consulting for development, production and quality 

control of drugs. 

Development, production and purification of monoclonal antibodies for use in diagnostics. 

Development and production of blood grouping reagents, Serafol ® bedside 

cards and test reagents for serotyping of Salmonellae, Shigellae, E. coli and Yersiniae. 

Development and production of culture media for microbiological diagnosis. 

Signature Diagnostics is dedicated to the discovery, validation and commercial development 

of novel diagnostic products that predict outcome and drug response in 

patients with colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and ovarian 

cancer. Signature believes that patient selection and stratification based on molecular 

gene signatures will soon become an important component of routine cancer treatment. 

Silence Therapeutics AG is a leading RNAi therapeutics development company and 

offers a novel, proprietary siRNA technology (AtuRNAi) and proprietary systemic delivery 

systems for siRNA (AtuPLEX, DACC and DBTC). SILENCE pipeline consists of 

both partnered and internal programs of which 3 clinical phase II and 1 clinical phase 

I programs are partnered with Pfizer/Quark (2 ophthalmic indications) and Novartis/ 

Quark (2 kidney indications). Silence?s internal lead compound Atu027 is currently in a 

Phase I clinical study for the treatment of solid tumours. 

SINA is a modern company providing elaborate services in molecular biology and 

protein biochemistry. Together with our industrial partners and customers from research 

institutions we develop complex cloning and mutagenesis strategies including 

high-throughput applications. We offer cloning of genes, expression and purification of 

proteins, DNA and RNA isolation from numerous biological materials and the production 

of competent cells with high transformation efficiency. 

Microbiological quality control for medical devices, pharmaceuticals, cosmetics, drinking 

water, foodstuff, monitoring in clean rooms. 

SOPAT is specialized in the analysis of particulate systems. The company develops and 

markets an innovative particle measurement technology for real-time analysis of multiphase 

systems. Particles, such as droplets, grains, cells or bubbles, are measured with 

high precision in running processes. 

STRATEC Molecular GmbH is a globally active provider of innovative system solutions 

for nucleic acid sample collection, stabilization, and both manual and automated purification 

from any sample type. Since 1992 the company is internationally respected for 

its outstanding and high performance technology platforms and offers a broad spectrum 

of superior products for molecular diagnostics, drug discovery and Life Science 

research. 

Strix Diagnostics is a medical diagnostics company specializing in customized development 

of certified analytical systems for multiparameter in vitro-diagnostics. 

Surflay Nanotec GmbH, a spin-off company from Capsulution NanoScience AG, is specialized 

on coating colloidal and planar materials with functional films. Key technology is 

the patented LbL-Technology ® with polymers. Applications are in the fields of separation 

materials, pigment encapsulation, bio-sensing and diagnostic particles. In addition 

to customer tailored projects Surflay offers an unique range of products of tunable 

multifunctional nano-or microparticles and dye-labeled polymers. 

rovalab.com 

royalbiotech.com 

scienion.de 

sepiatec.com 

seramun.com 

institut-fresenius.de 

sifin.de 

signature-diagnostics.de 

silence-therapeutics.com 

sina-science-services.de 

speziallabor.com 

sopat.de 

invitek.de 

strix-diagnostics.de 

surflay.com 

58




t-cell Europe GmbH 

Thanares GmbH 

t-cell Europe GmbH, a spin-off of the Berlin Brandenburg Center for Regenerative Medicines 

(BCRT), is aiming to become the world’s technology leader in the application 

of T-cell-based therapies used in transplantation medicine. Over the next few years, 

with its three proprietary platform technologies, the company will develop and clinically 

validate novel T-cell-based products and corresponding diagnostics to regulate the 

immune system and treat viral infections. The company’s lead reference product will 

be a first-in-class Treg cell product/therapy for kidney transplantation that suppresses 

organ rejection in recipients 

Development, use and marketing of analytical process for diagnostic and therapeutic 

purposes. Future business activities: detection process for bioactive substances in 

bodily fluids, isolation, characterization and investigation of bioactive compounds from 

plants, in particular insoluble proteins or low concentrations of proteins, development 

of low cost genetic systems for over-expression and/or production of such proteins. 

t-cell.de 

thanares.com 

TheraKine BioDelivery GmbH Development of antibody drug delivery systems and related tasks. therakine.com 

Thermo Fisher Scientific – 

B·R·A·H·M·S GmbH 

TIB MOLBIOL Syntheselabor 

GmbH 

TissUse GmbH 

TransTissue Technologies GmbH 

UGA Biopharma GmbH 

Umwelttechnik-Berlin UG 

Zellwerk GmbH 

Zentrum für molekulare 

Onkologie GmbH 

Zytomed Systems GmbH 

Thermo Scientific Biomarkers (B·R·A·H·M·S GmbH) explores, develops and produces 

new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of 

life-threatening illnesses. This takes place with over 470 employees, in the disease areas 

infectiology, cardiology and pneumology as well as thyroid, autoimmunity and cardiology 

on the basis of our own patented biomarkers. Since October 2009 B·R·A·H·M·S 

GmbH is part of Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving 

science. 

In 1990, TIB MOLBIOL became the first German manufacturer of oligonucleotides. In 

addition to designing and synthesizing primers and probes for Real-Time PCR assays, 

we develop and produce LightMix ® Kits for Roche Diagnostics LightCycler ® Instruments, 

covering applications in Clinical Chemistry, Pharmacogenetics, Pathogen Detection, as 

well as Cancer Research. TIB MOLBIOL is ISO 13485 and ISO 9001 certified. 

TissUse is a vibrant growth company providing high-value services in the area of tissue 

culture analysis of drug candidates, cosmetics, chemicals and consumer products. 

TransTissue has been a subsidiary of BioTissue Technologies, Freiburg since September 

2001. With more than 15 years of experience in regenerative medicine, the scientists 

of TransTissue Technologies have developed second-generation autologous tissue 

replacements, e.g. cartilage and bone grafts. We are mainly concerned with inventions 

and the development of tissue engineering products for regenerative medicine. We 

offer a broad panel of services in the field of regenerative medicine. 

UGA Biopharma a private Research and Development company, focuses on Research, 

Development and Commercialization of Biopharmaceutical products under contract 

with other Biopharmaceutical companies. UGA Biopharma conducts power of biosciences 

to develop high-tech, last generation of biomedicine, diagnostic kits, molecular 

biology items and also offers world class services in biotechnology area. 

Feasibility studies, development, planning, construction and operation of biotechnological 

plants for groundwater, process water and waste water purification. Accredited 

microbiological laboratory for the investigation of drinking water, groundwater, bath 

water, soils, food, anti-microbial active ingredients and sterility according to Ph.Eur, 

approved in accordance with BiostoffV and the German infection protection act (Infektionsschutzgesetz). 

Zellwerk produces the proprietary Z ® RP cell cultivation system, comprising rotating 

bed bioreactor, GMP Breeder, Control Unit, software. Bioreactors with 50-5000 ml volume, 

0,2-2 m² seeding surface, different cell carriers, can be delivered. In this culturing 

system cells grow tissue-like, being embedded in self-generated extra-cellular matrix. 

The technology opens unique opportunities for the GMP-compliant expansion of stem 

cells and primary cells, manufacturing of cell-seeded implants as well as production 

of recombinant proteins. In addition, we have recently developed a new bioreactor for 

expansion of immune cells for cell therapy of leukemia and several types of cancer. 

Innovative methods for diagnostic and therapy of tumor diseases - Molecular genetics 

(K-RAS, PCA3, Septin9, ...) - Chemoresistance assay for prediction of chemotherapy - 

Pathology Development of new biomarkers and analytical services for studies. 

Zytomed Systems´ focus is the development, production and distribution of antibodies 

and detection systems for immunohistochemical cancer diagnostics as well as reagents 

and kits for in-situ hybridisation. 

thermoscientific.com/ 

brahms 

tib-molbiol.com 

tissuse.com 

transtissue.com 

ugabiopharma.com 

bartetzko.com 

zellwerk.biz 

molekulare-onkologie.eu 

zytomed-systems.de 

59

BioTOP is a joint initiative of the state of Berlin and the state of Brandenburg under the umbrella of the Berlin Partner für Wirtschaft und Technologie GmbH and takes part in the 

Cluster Management HealthCapital. BioTOP is funded by the federal state of Berlin, the federal state of Brandenburg and the Investitionsbank Berlin, co-funded by the European 

Union (European Fund for Regional Development). Investing in your Future

BioTOP Report 2014

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?